BioMedLib Search Engine [ goto HOMEPAGE ]

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Molecular pathology of well-differentiated thyroid carcinomas.

The newly discovered molecular features of well-differentiated thyroid carcinomas derived from follicular cells are reviewed, within the frame of the 2004 WHO classification of thyroid tumours, under the following headings: "Follicular carcinoma", "Papillary carcinoma", "Follicular variant of papillary carcinoma" and "Hürthle cell tumours".

A particular emphasis is put on the meaning of PAX8-PPARgamma rearrangements, RAS and BRAF mutations, and deletions and mutations of mitochondrial genes and of nuclear genes encoding for mitochondrial enzymes, for thyroid tumorigenesis.

[MeSH-major] Adenoma, Oxyphilic / genetics. Carcinoma, Papillary, Follicular / genetics. Gene Rearrangement. Thyroid Neoplasms / genetics

MedlinePlus Health Information. consumer health - Thyroid Cancer.

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

SciCrunch. KEGG: Data: Disease Annotation .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Lab Invest. 1981 Oct;45(4):336-41 [7300245.001]

[Cites] Ultrastruct Pathol. 1985;8(2-3):131-42 [4060255.001]

[Cites] J Pathol. 1998 Nov;186(3):292-9 [10211119.001]

[Cites] Int J Cancer. 1997 Jan 6;70(1):32-8 [8985087.001]

[Cites] J Clin Invest. 1992 May;89(5):1517-22 [1569189.001]

[Cites] Mod Pathol. 2000 Aug;13(8):861-5 [10955452.001]

[Cites] Am J Surg Pathol. 2002 Aug;26(8):1016-23 [12170088.001]

[Cites] J Pathol. 2005 Jul;206(3):305-11 [15852498.001]

[Cites] Gastroenterology. 1995 Apr;108(4):1040-7 [7698570.001]

[Cites] Am J Pathol. 1998 Oct;153(4):1201-9 [9777951.001]

[Cites] Ultrastruct Pathol. 1998 Jan-Feb;22(1):91-100 [9491221.001]

[Cites] Virchows Arch. 2000 Aug;437(2):107-15 [10993269.001]

[Cites] Am J Clin Pathol. 2003 Jul;120(1):71-7 [12866375.001]

[Cites] Am J Surg Pathol. 2004 Oct;28(10):1336-40 [15371949.001]

[Cites] Endocr Pathol. 2002 Spring;13(1):3-16 [12114746.001]

[Cites] Int J Surg Pathol. 2005 Jan;13(1):29-35 [15735852.001]

[Cites] Hum Pathol. 2005 Jun;36(6):694-7 [16021577.001]

[Cites] Virchows Arch. 2004 Jun;444(6):572-6 [15095090.001]

[Cites] Oncogene. 2003 Jul 17;22(29):4578-80 [12881714.001]

[Cites] Cell Oncol. 2004;26(5-6):301-5 [15623940.001]

[Cites] Nature. 2002 Jun 27;417(6892):949-54 [12068308.001]

[Cites] Cytogenet Cell Genet. 1994;66(4):253-9 [7909283.001]

[Cites] J Pathol. 2001 Jul;194(3):358-66 [11439369.001]

[Cites] J Clin Endocrinol Metab. 2002 Aug;87(8):3947-52 [12161538.001]

[Cites] Clin Cancer Res. 1998 Feb;4(2):287-94 [9516913.001]

[Cites] Am J Surg Pathol. 1983 Dec;7(8):809-17 [6660353.001]

[Cites] Eur J Cancer. 1997 Feb;33(2):293-6 [9135503.001]

[Cites] J Clin Endocrinol Metab. 2003 May;88(5):2318-26 [12727991.001]

[Cites] Am J Surg Pathol. 1993 Mar;17(3):291-301 [8434709.001]

[Cites] Int J Surg Pathol. 2005 Jul;13(3):235-8 [16086077.001]

[Cites] N Engl J Med. 2005 Jun 9;352(23):2406-12 [15944425.001]

[Cites] Am J Clin Pathol. 1982 Jan;77(1):20-5 [7055095.001]

[Cites] J Clin Endocrinol Metab. 2000 Feb;85(2):878-82 [10690905.001]

[Cites] Mol Endocrinol. 2002 May;16(5):903-11 [11981026.001]

[Cites] J Biol Chem. 2000 Oct 27;275(43):33416-26 [10924506.001]

[Cites] Cancer. 2001 Nov 15;92(10):2529-38 [11745186.001]

[Cites] Pathol Int. 1995 Jan;45(1):45-50 [7704243.001]

[Cites] Science. 2000 Aug 25;289(5483):1357-60 [10958784.001]

[Cites] Am J Pathol. 2002 May;160(5):1857-65 [12000737.001]

[Cites] Cell. 2004 Mar 19;116(6):855-67 [15035987.001]

[Cites] Cancer Res. 2003 Apr 1;63(7):1454-7 [12670889.001]

[Cites] Am J Surg Pathol. 1998 Dec;22(12):1512-20 [9850177.001]

[Cites] Virchows Arch. 2001 Apr;438(4):336-42 [11355166.001]

[Cites] J Clin Endocrinol Metab. 2003 Nov;88(11):5399-404 [14602780.001]

[Cites] Nat Rev Cancer. 2003 Mar;3(3):193-202 [12612654.001]

[Cites] J Pathol. 1998 May;185(1):71-8 [9713362.001]

[Cites] Am J Surg Pathol. 1977 Jun;1(2):123-30 [602974.001]

[Cites] Genes Chromosomes Cancer. 2004 Aug;40(4):355-64 [15188460.001]

[Cites] Lab Invest. 1999 May;79(5):547-55 [10334566.001]

[Cites] J Clin Endocrinol Metab. 2003 Sep;88(9):4440-5 [12970322.001]

[Cites] J Natl Cancer Inst. 2003 Apr 16;95(8):625-7 [12697856.001]

[Cites] Oncogene. 2004 Sep 23;23(44):7436-40 [15273715.001]

[Cites] Br J Cancer. 2005 May 23;92(10):1892-8 [15841082.001]

[Cites] Int J Cancer. 1990 Jan 15;45(1):16-20 [2298499.001]

[Cites] J Pathol. 2004 Feb;202(2):247-51 [14743508.001]

[Cites] Endocr Pathol. 2002 Winter;13(4):313-20 [12665649.001]

[Cites] J Pathol. 2000 Jul;191(3):274-81 [10878549.001]

[Cites] J Clin Endocrinol Metab. 2003 Jan;88(1):354-7 [12519876.001]

[Cites] J Clin Endocrinol Metab. 2003 Sep;88(9):4393-7 [12970315.001]

[Cites] Surgery. 1994 Dec;116(6):1010-6 [7985080.001]

[Cites] Virchows Arch. 2005 Jun;446(6):589-95 [15902486.001]

[Cites] EMBO J. 2001 Jul 16;20(14):3716-27 [11447113.001]

[Cites] J Clin Endocrinol Metab. 2004 Sep;89(9):4267-71 [15356020.001]

[Cites] J Pathol. 2004 Mar;202(3):352-8 [14991901.001]

[Cites] Mol Endocrinol. 1990 Oct;4(10):1474-9 [2283998.001]

[Cites] Cancer. 1985 Feb 15;55(4):805-28 [3967175.001]

[Cites] J Pathol. 2000 Dec;192(4):561-2 [11113879.001]

[Cites] Eur J Endocrinol. 2002 Jan;146(1):27-33 [11751063.001]

(PMID = 16189702.001).

[ISSN] 0945-6317

[Journal-full-title] Virchows Archiv : an international journal of pathology

[ISO-abbreviation] Virchows Arch.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review

[Publication-country] Germany

[Chemical-registry-number] 0 / PAX8 Transcription Factor; 0 / PAX8 protein, human; 0 / PPAR gamma; 0 / Paired Box Transcription Factors; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf

[Number-of-references] 70

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] A case of acromegaly and disseminated follicular thyroid carcinoma.

INTRODUCTION: A particularly challenging case of concurrent acromegaly and follicular thyroid carcinoma in a patient of the Clinic of Endocrinology, UJCM in Krakow is discussed.

CASE DESCRIPTION: A 59-year-old male with post total thyroidectomy performed in 2005 and histopathologically confirmed metastases of the follicular thyroid carcinoma to the lungs was admitted to the Clinic in April 2006 for complementary ¹³¹I treatment.

Pre-therapeutic whole-body scintigraphy (WBS) revealed numerous conjoined hot spots of ¹³¹I accumulation in both lungs and in thyroid remnants.

Post-therapeutic WBS in November 2006 revealed complete ablation of the thyroid remnants.

CONCLUSIONS: Disseminated thyroid cancer in a patient with pituitary insufficiency may be successfully treated by rhTSH-supported ¹³¹I treatment.

[MeSH-major] Acromegaly / etiology. Neoplasm Recurrence, Local / diagnosis

[MeSH-minor] Adenocarcinoma, Follicular. Humans. Iodine Radioisotopes / therapeutic use. Lung Neoplasms / diagnostic imaging. Lung Neoplasms / secondary. Male. Middle Aged. Radionuclide Imaging. Thyroglobulin / therapeutic use. Thyroid Neoplasms / complications. Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / secondary. Thyroid Neoplasms / therapy. Thyroidectomy

Genetic Alliance. consumer health - Acromegaly.

Hazardous Substances Data Bank. THYROGLOBULIN .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 21049465.001).

[ISSN] 0423-104X

[Journal-full-title] Endokrynologia Polska

[ISO-abbreviation] Endokrynol Pol

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Poland

[Chemical-registry-number] 0 / Iodine Radioisotopes; 9010-34-8 / Thyroglobulin

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Immunohistochemical study of oestrogen receptors in 351 human thyroid glands.

INTRODUCTION: It is well recognised that the pathogenesis of thyroid diseases is complex and different factors such as genetic factors, iodine deficiency, sex, age, radiation therapy in childhood, growth stimulating antibodies, and other epithelial growth factors can influence them.

Epidemiological features of thyroid tumours and experimental evidence suggest that female sex hormones may exert effects on the thyroid gland and its neoplasms.

This possibility was addressed by investigating the expression of oestrogen receptor protein in 351 thyroid lesions.

METHODS: The tissues from 351 human thyroid glands comprising 130 nodular goitres and 221 neoplastic lesions were used for the present immunohistochemical assessment of oestrogen receptor expression.

RESULTS: Incidence of oestrogen receptor positive cases were 24 percent (31/130) for nodular goitres, 22 percent (8/37) for follicular adenomas, 11 percent (2/18) for follicular carcinomas, 31 percent (37/119) for papillary carcinomas, zero percent (0/35) for medullary carcinomas and zero percent (0/12) for undifferentiated carcinomas.

The incidence of oestrogen receptor positivity, which is compatible with other studies, is higher in well-differentiated thyroid lesions.

CONCLUSION: The relatively high proportion of oestrogen receptor positivity in goitres, follicular adenomas and papillary carcinomas, compared with its reactivity in other thyroid neoplasms, and contrasted against normal thyroid tissue, suggests that the incidence of oestrogen receptor reactivity tends to increase with better differentiation of thyroid lesions.

This finding may have clinical relevance.

[MeSH-major] Goiter / metabolism. Receptors, Estrogen / metabolism. Thyroid Gland / metabolism. Thyroid Neoplasms / metabolism

[MeSH-minor] Adenocarcinoma, Follicular / metabolism. Adenoma / metabolism. Adult. Carcinoma, Papillary / metabolism. Female. Humans. Immunohistochemistry. Male

MedlinePlus Health Information. consumer health - Thyroid Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17657383.001).

[ISSN] 0037-5675

[Journal-full-title] Singapore medical journal

[ISO-abbreviation] Singapore Med J

[Language] eng

[Publication-type] Journal Article

[Publication-country] Singapore

[Chemical-registry-number] 0 / Receptors, Estrogen

   

Advertisement

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Urokinase receptor, MMP-1 and MMP-9 are markers to differentiate prognosis, adenoma and carcinoma in thyroid malignancies.

The identification of high-risk patients with thyroid cancer and the preoperative differentiation between follicular adenoma and carcinoma remain clinically challenging.

Our study was conducted to analyze whether the quantification of matrix metalloproteinases (MMPs) and urokinase-type plasminogen activator receptor (u-PAR) and transcription factor binding to the u-PAR promoter improve prognostic predictability and differential diagnosis of thyroid tumors.

Tumor/normal tissue was collected from 69 prospectively followed patients with thyroid carcinomas (papillary, medullary, follicular and anaplastic, PTC, MTC, FTC and ATC) or follicular adenomas.

Carcinomas except MTC expressed significantly more u-PAR/MMPs than adenomas/normal tissues, this being associated with advanced pT- or M-stages.

MMP-1 and MMP-9 were significantly higher in follicular carcinomas than in adenomas.

In carcinomas, high u-PAR-gene expression correlated significantly with high MMP-9, the latter being associated with MMP-7 in normal tissues.

Poor survival in differentiated tumors was associated in trend (p = 0.07); poor survival of all patients (p = 0.043) and especially of patients with carcinomas of follicular origin (including ATC), but not medullary carcinomas, were significantly associated with high u-PAR-protein (p = 0.015).

Quantification of u-PAR is of prognostic relevance in thyroid carcinomas of non-c-cell origin, and u-PAR in part may be regulated nontranscriptionally in thyroid cancers.

This is the first study to suggest MMP-1/-9 as significant differentiation markers between follicular adenoma and follicular carcinoma.

[MeSH-major] Adenoma / metabolism. Biomarkers, Tumor / metabolism. Matrix Metalloproteinase 1 / metabolism. Matrix Metalloproteinase 9 / metabolism. Receptors, Urokinase Plasminogen Activator / metabolism. Thyroid Neoplasms / metabolism

[MeSH-minor] Adenocarcinoma, Follicular / metabolism. Adenocarcinoma, Follicular / pathology. Adult. Aged. Blotting, Western. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / pathology. Electrophoretic Mobility Shift Assay. Female. Humans. Immunoenzyme Techniques. Luciferases. Male. Matrix Metalloproteinase 7 / metabolism. Middle Aged. Prognosis. Promoter Regions, Genetic / genetics. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Transfection

MedlinePlus Health Information. consumer health - Thyroid Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19480010.001).

[ISSN] 1097-0215

[Journal-full-title] International journal of cancer

[ISO-abbreviation] Int. J. Cancer

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / Receptors, Urokinase Plasminogen Activator; EC 1.13.12.- / Luciferases; EC 3.4.24.23 / MMP7 protein, human; EC 3.4.24.23 / Matrix Metalloproteinase 7; EC 3.4.24.35 / Matrix Metalloproteinase 9; EC 3.4.24.7 / Matrix Metalloproteinase 1

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] The influence of gender, age, and RET polymorphisms on C-cell hyperplasia and medullary thyroid carcinoma.

BACKGROUND: RET germline mutations predispose to the development of hereditary medullary thyroid carcinoma (hMTC).

However, the findings regarding their influence on the clinical course and biological behavior of this disorder are discordant.

To clarify the contradictory findings, we studied the association of certain SNPs considering age, gender, and histopathology in a large Austrian cohort with C-cell hyperplasia (CCH) and MTC.

METHODS: Genotyping of SNPs located in RET codons 691, 769, 836, and 904 from 199 patients with MTC and CCH (basal calcitonin > 10 pg/mL, pentagastrin stimulated > 100 pg/mL) was performed, and the results were analyzed considering gender, age at diagnosis, and histopathology.

In sMTC and sporadic CCH (sCCH) no significant association of SNP frequency with the age at diagnosis was found.

In patients with sporadic C-cell disease (sCCH and sMTC), 3.7 times more males than females suffered synchronously from papillary or follicular thyroid cancer (20/97 [20.6%] males; 3/54 [5.6%] females; p = 0.02).

In contrast to males, the ratio of CCH to total C-cell disease was significantly higher in females with hereditary (26/32, 81%) compared to those with sporadic disease (27/54, 50%; p = 0.006).

CONCLUSIONS: In this study RET SNPs had no clinical impact on the development of sporadic C-cell disease when the age of diagnosis or gender is considered.

C-cell disease seems to predispose males to the development of papillary and follicular thyroid cancer.

[MeSH-major] Carcinoma, Medullary / genetics. Proto-Oncogene Proteins c-ret / genetics. Thyroid Gland / pathology. Thyroid Neoplasms / genetics

[MeSH-minor] Adult. Age Factors. Aged. Calcitonin / blood. Female. Gene Frequency. Humans. Hyperplasia / pathology. Male. Middle Aged. Polymorphism, Single Nucleotide. Sex Factors. Thyroidectomy

MedlinePlus Health Information. consumer health - Thyroid Cancer.

Hazardous Substances Data Bank. Calcitonin .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18976163.001).

[ISSN] 1557-9077

[Journal-full-title] Thyroid : official journal of the American Thyroid Association

[ISO-abbreviation] Thyroid

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 9007-12-9 / Calcitonin; EC 2.7.10.1 / Proto-Oncogene Proteins c-ret

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Pediatric thyroid cancer arising after treatment for pleuropulmonary blastoma.

Open biopsy revealed the pathological diagnosis of pleuropulmonary blastoma.

Three years later, follicular carcinoma of the right thyroid lobe was found, so a right hemithyroidectomy was performed.

Five months later, the thyroid tumor recurred.

The remaining thyroid lobe was completely excised and radioiodine therapy was administered.

The etiology and treatment of the uncommon combination of pleuropulmonary blastoma and thyroid carcinoma is discussed.

[MeSH-major] Adenocarcinoma, Follicular / pathology. Lung Neoplasms / pathology. Neoplasms, Second Primary / pathology. Pulmonary Blastoma / pathology. Thyroid Neoplasms / pathology

Genetic Alliance. consumer health - Pleuropulmonary blastoma.

Genetic Alliance. consumer health - Blastoma.

Genetic Alliance. consumer health - Thyroid Cancer.

MedlinePlus Health Information. consumer health - Lung Cancer.

MedlinePlus Health Information. consumer health - Thyroid Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] (c) 2008 Wiley-Liss, Inc.

[CommentIn] Pediatr Blood Cancer. 2008 May;50(5):1081 [18000857.001]

(PMID = 17514738.001).

[ISSN] 1545-5017

[Journal-full-title] Pediatric blood & cancer

[ISO-abbreviation] Pediatr Blood Cancer

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Iodine Radioisotopes

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Aberrant accumulation of PTTG1 induced by a mutated thyroid hormone beta receptor inhibits mitotic progression.

Overexpression of pituitary tumor-transforming 1 (PTTG1) is associated with thyroid cancer.

We found elevated PTTG1 levels in the thyroid tumors of a mouse model of follicular thyroid carcinoma (TRbeta(PV/PV) mice).

Here we examined the molecular mechanisms underlying elevated PTTG1 levels and the contribution of increased PTTG1 to thyroid carcinogenesis.

We showed that PTTG1 was physically associated with thyroid hormone beta receptor (TRbeta) as well as its mutant, designated PV.

Concomitant with thyroid hormone-induced (T3-induced) degradation of TRbeta, PTTG1 proteins were degraded by the proteasomal machinery, but no such degradation occurred when PTTG1 was associated with PV.

The loss of this regulatory function in PV led to an aberrant accumulation of PTTG1 disrupting mitotic progression that could contribute to thyroid carcinogenesis.

COS Scholar Universe. author profiles.

KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).

Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

SciCrunch. OMIM: Data: Gene Annotation .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Oncogene. 2000 Jan 20;19(3):403-9 [10656688.001]

[Cites] Cell. 2006 Jan 27;124(2):381-92 [16439211.001]

[Cites] Proc Natl Acad Sci U S A. 2000 Aug 1;97(16):8985-90 [10908671.001]

[Cites] Mol Endocrinol. 2000 Aug;14(8):1137-46 [10935539.001]

[Cites] J Biol Chem. 2000 Nov 24;275(47):36502-5 [11013229.001]

[Cites] Proc Natl Acad Sci U S A. 2000 Nov 21;97(24):13209-14 [11069286.001]

[Cites] Brain Pathol. 2001 Jul;11(3):328-41 [11414475.001]

[Cites] Mol Cell Biol. 2001 Oct;21(20):6782-95 [11564863.001]

[Cites] J Clin Endocrinol Metab. 2001 Oct;86(10):5025-32 [11600580.001]

[Cites] Mol Endocrinol. 2002 Sep;16(9):2077-92 [12198244.001]

[Cites] Thyroid. 2002 Nov;12(11):963-9 [12490073.001]

[Cites] Genes Chromosomes Cancer. 2003 Mar;36(3):292-302 [12557229.001]

[Cites] Cancer Genet Cytogenet. 2003 Feb;141(1):26-31 [12581895.001]

[Cites] Trends Endocrinol Metab. 2003 Sep;14(7):327-33 [12946875.001]

[Cites] Carcinogenesis. 2003 Sep;24(9):1467-79 [12869418.001]

[Cites] Clin Otolaryngol Allied Sci. 2003 Oct;28(5):386-95 [12969338.001]

[Cites] Cancer Res. 2003 Sep 1;63(17):5274-80 [14500358.001]

[Cites] Endocrinology. 2003 Nov;144(11):4991-8 [12960092.001]

[Cites] Methods Enzymol. 2003;364:257-84 [14631850.001]

[Cites] Arch Biochem Biophys. 2004 May 15;425(2):158-64 [15111123.001]

[Cites] J Biol Chem. 2004 Aug 6;279(32):33909-18 [15166217.001]

[Cites] Mol Endocrinol. 1991 Apr;5(4):485-92 [1922081.001]

[Cites] J Clin Invest. 1991 Dec;88(6):2123-30 [1661299.001]

[Cites] Mol Endocrinol. 1992 Feb;6(2):248-58 [1569968.001]

[Cites] Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7737-41 [1502193.001]

[Cites] J Clin Invest. 1993 Oct;92(4):1986-93 [8408652.001]

[Cites] Biochemistry. 1995 Aug 22;34(33):10591-9 [7544615.001]

[Cites] Mol Endocrinol. 1997 Apr;11(4):433-41 [9092795.001]

[Cites] Genes Chromosomes Cancer. 1997 May;19(1):43-51 [9135994.001]

[Cites] Cell. 1998 Apr 3;93(1):81-91 [9546394.001]

[Cites] Oncogene. 1998 Oct 29;17(17):2187-93 [9811450.001]

[Cites] J Clin Endocrinol Metab. 1999 Feb;84(2):761-7 [10022450.001]

[Cites] Science. 1999 Jul 16;285(5426):418-22 [10411507.001]

[Cites] Mol Cell Biol. 2005 Jan;25(1):124-35 [15601836.001]

[Cites] Trends Biochem Sci. 2005 Mar;30(3):126-32 [15752984.001]

[Cites] Trends Endocrinol Metab. 2005 May-Jun;16(4):176-82 [15860414.001]

[Cites] Oncogene. 2005 Jul 14;24(30):4861-6 [15897900.001]

[Cites] Cancer Genet Cytogenet. 2005 Sep;161(2):104-9 [16102579.001]

[Cites] Cancer Treat Res. 2004;122:85-105 [16209039.001]

[Cites] Lancet. 2000 Feb 26;355(9205):716-9 [10703804.001]

(PMID = 17039256.001).

[ISSN] 0021-9738

[Journal-full-title] The Journal of clinical investigation

[ISO-abbreviation] J. Clin. Invest.

[Language] ENG

[Grant] United States / Intramural NIH HHS / /

[Publication-type] Journal Article; Research Support, N.I.H., Intramural

[Publication-country] United States

[Chemical-registry-number] 0 / Ligands; 0 / Neoplasm Proteins; 0 / RNA, Small Interfering; 0 / Securin; 0 / Thyroid Hormone Receptors beta; EC 3.4.25.1 / Proteasome Endopeptidase Complex

[Other-IDs] NLM/ PMC1592548

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Transliterated title] La tiroidectomia totale di principio nel microcarcinoma papillare.

INTRODUCTION: Today, the "gold standard" of surgical management of benign thyroid disease is still controversy.

There are different surgical approaches to the thyroid gland, from a radical, total thyroidectomy to a conservative treatment, lobectomy with or not isthmectomy.

In consideration of the more frequent incidence of small carcinomas accidentally founded in the context of the thyroid parenchyma removed for another pathology, the aim of this study is to bring a contribute to resolve the debate on the therapeutic choice in the surgical management of the thyroid benign disease.

PATIENTS AND METHODS: From January 2000 to January 2006 502 thyroidectomy were performed in the Section of General and Thoracic Surgery of University of Palermo: 458 total thyroidectomy (91.3%), 2 partial thyroidectomy (0.3%), 24 (4.8%) lobectomy with isthmectomy and 18 (3.6%) reinterventions for relapse; 34 patients (6.8%) were preoperative suspected (cytological or ultrasonography) for thyroid cancer.

Histologically, were 11 cases of classical papillary (64.7%), 4 cases (23.6%) of follicular and 2 (11.7%) sclerosing, in 9 cases of multinodular goiter, 3 of follicular adenoma, 3 cases of follicular carcinoma, 1 case of Graves disease and 1 case of Hashimoto thyroiditis.

DISCUSSION: Papillary microcarcinoma is a "thyroid papillary cancer with a diameter < or = 1 cm? ".

CONCLUSIONS: In our opinion, the surgical management of the all thyroid disease must be the more radical since the first time, because we think other approaches not correct to improve the complete health from the benign thyroid disease and to prevent (secondary prevention) papillary microcarcinoma not pre-operative diagnosed, because there are no preoperative pattern to make a correct diagnosis of this tumour.

[MeSH-major] Carcinoma, Papillary / surgery. Thyroid Neoplasms / surgery. Thyroidectomy / methods

MedlinePlus Health Information. consumer health - Thyroid Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17313727.001).

[ISSN] 0391-9005

[Journal-full-title] Il Giornale di chirurgia

[ISO-abbreviation] G Chir

[Language] ita

[Publication-type] English Abstract; Journal Article

[Publication-country] Italy

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Does Hurthle cell lesion/neoplasm predict malignancy more than follicular lesion/neoplasm on thyroid fine-needle aspiration?

Thyroid fine-needle aspiration (FNA) is a standard procedure for the clinical triage of thyroid nodules.

The diagnosis of an adequately sampled thyroid FNA is generally grouped into three categories: benign, malignant, and indeterminate.

The latter group usually includes follicular neoplasm, follicular lesion, and sometimes a more specific diagnosis such as Hurthle cell neoplasm or follicular lesion/neoplasm with Hurthle cell change.

Whether a FNA diagnosis of Hurthle cell lesion/neoplasm (HLN) denotes a worse clinical outcome than follicular lesion/neoplasm (FLN) remains controversial.

A cohort of 303 thyroid FNA cases with follow-up thyroidectomy in our institutes was identified, with the follow-up excision diagnosis compared to the FNA diagnosis in order to address this issue.

Of this cohort, 87 cases had an FNA diagnosis of HLN while 216 cases had a diagnosis of FLN.

Upon excision, the FNA diagnosis of HLN group had 14 cases of goiter/nodular hyperplasia (16%), 46 cases of adenoma (12 follicular adenoma (14%) and 34 cases of Hurthle cell adenoma (39%)), and 27 cases of carcinoma (31%, 12 papillary carcinoma and 15 Hurthle cell carcinoma).

The FLN group had 74 cases of goiter/nodular hyperplasia (34.3%), 8 cases of Hashimoto thyroiditis (3.7%), 73 cases of follicular adenoma (33.8%), one case of granular cell tumor, and 60 cases of carcinoma (27.8%, 46 papillary carcinoma, 12 follicular carcinoma, and 1 Hurthle cell carcinoma and 1 parathyroid carcinoma) upon excision.

There is no significant difference in predicting cancer between the two cytology diagnosis groups (HLN versus FLN, 31% versus 27.8%, P = 0.5771).

When sorting all the cases by the surgical diagnosis, while comparable for age at diagnosis, the cancer group having the higher proportion of male patients than the non-cancer group (28.7% versus 16.7%, P = 0.0259).

Hurthle cell carcinoma patients are typically older than patients with other cancer diagnoses (59 versus 44, P = 0.0077).

Our results suggest that an FNA diagnosis of HLN does not predict more malignancy than FLN.

Males and older patients with a HLN FNA diagnosis carry a higher risk of Hurthle cell carcinoma upon thyroidectomy.

[MeSH-major] Adenocarcinoma, Follicular / pathology. Adenoma / pathology. Adenoma, Oxyphilic / pathology. Biopsy, Fine-Needle / methods. Oxyphil Cells / pathology. Thyroid Neoplasms / pathology

[MeSH-minor] Adenocarcinoma, Papillary / pathology. Adenocarcinoma, Papillary / surgery. Adolescent. Adult. Aged. Aged, 80 and over. Cohort Studies. Female. Goiter, Nodular / pathology. Goiter, Nodular / surgery. Humans. Hyperplasia / pathology. Hyperplasia / surgery. Male. Middle Aged. Prognosis. Thyroid Nodule / pathology. Thyroid Nodule / surgery. Thyroidectomy

MedlinePlus Health Information. consumer health - Thyroid Cancer.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16604553.001).

[ISSN] 8755-1039

[Journal-full-title] Diagnostic cytopathology

[ISO-abbreviation] Diagn. Cytopathol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines.

OBJECTIVE: To investigate the regulation of the breast cancer resistance protein ABCG2/BRCP1 drug transporter by epidermal growth factor receptor (EGFR) kinase activity, and to determine whether gefitinib, an EGFR small molecule inhibitor, will modulate the effects of doxorubicin hydrochloride by inhibiting its extrusion from thyroid cancer cells.

DESIGN: Extrusion assays using flow cytometry analysis were used to determine the ability of thyroid cancer cells to extrude the chemotherapy drug, doxorubicin, via the ABCG2 drug transporter in the presence or absence of gefitinib.

The ABCG2 expression in ARO and WRO cell lines was analyzed by Western blot analysis.

Colony formation assays were performed to determine the effect of gefitinib on thyroid cancer cell survival in response to gefitinib, doxorubicin, or the combination of both drugs.

RESULTS: Inhibition of EGFR kinase activity by gefitinib causes the translocation of the ABCG2 drug transporter away from the plasma membrane, resulting in a concomitant decrease in doxorubicin extrusion in thyroid cancer cell lines.

The addition of gefitinib increases doxorubicin-induced cell death in thyroid cancer cells as measured by colony formation assay.

Inactivation of the EGFR kinase by gefitinib potentiates the cytotoxic effect of doxorubicin in thyroid cancer, most likely by decreasing the ability of the cell to extrude doxorubicin.

The expression of ABCG2 may explain in part the ineffectiveness of doxorubicin as a single modality treatment for anaplastic thyroid cancer or for treatment of metastatic follicular thyroid cancer.

Use of this combination treatment of gefitinib and doxorubicin may be a promising therapy for anaplastic thyroid and metastatic follicular thyroid cancer and needs to be investigated further.

[MeSH-major] ATP-Binding Cassette Transporters / genetics. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug Resistance, Neoplasm / drug effects. Gene Expression Regulation, Neoplastic. Neoplasm Proteins / genetics. RNA, Neoplasm / genetics. Thyroid Neoplasms / drug therapy

[MeSH-minor] ATP Binding Cassette Transporter, Sub-Family G, Member 2. Antineoplastic Agents / therapeutic use. Apoptosis / drug effects. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Blotting, Western. Carcinoma / drug therapy. Carcinoma / metabolism. Carcinoma / pathology. Cell Line, Tumor. Cell Proliferation / drug effects. Culture Media. Doxorubicin / administration & dosage. Drug Resistance, Multiple. Flow Cytometry. Fluorescent Antibody Technique. Humans. In Situ Nick-End Labeling. Quinazolines / administration & dosage. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Receptor, Epidermal Growth Factor / metabolism

Genetic Alliance. consumer health - Thyroid Cancer.

MedlinePlus Health Information. consumer health - Thyroid Cancer.

Hazardous Substances Data Bank. DOXORUBICIN .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17938326.001).

[ISSN] 0886-4470

[Journal-full-title] Archives of otolaryngology--head & neck surgery

[ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / ABCG2 protein, human; 0 / ATP Binding Cassette Transporter, Sub-Family G, Member 2; 0 / ATP-Binding Cassette Transporters; 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Culture Media; 0 / Neoplasm Proteins; 0 / Quinazolines; 0 / RNA, Neoplasm; 80168379AG / Doxorubicin; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Primary thyroid-like follicular carcinoma of the kidney: report of 6 cases of a histologically distinctive adult renal epithelial neoplasm.

Thyroidization of kidney reminiscent of thyroid follicles with accumulation of inspissated colloid-like material in renal tubules is a hallmark of chronic pyelonephritis.

We identified 6 tumors in the kidney, distinct from currently known subtypes of renal cell carcinoma, with a striking histology that closely mimicked well-differentiated thyroid follicular neoplasms and raised the possibility of metastatic follicular thyroid carcinoma.

All tumors were encapsulated and exclusively demonstrated follicular architecture comprising of microfollicles and macrofollicles containing inspissated colloid-like material.

The tumors were nonimmunoreactive with thyroglobulin and thyroid transcription factor 1 and for markers contemporarily used for renal differentiation.

The tumors had a gene expression profile distinct from clear cell and chromophobe renal cell carcinoma.

Mean follow-up of 47.3 months (range: 7 to 84 mo) showed that 5 patients had no evidence of disease and 1 developed a metastasis to the renal hilar lymph nodes in which the follicular architecture with colloid was retained.

Thyroid-like follicular renal cell carcinoma represents a unique histologic subtype of renal cell carcinoma of low malignant potential and its primary importance is to distinguish it from metastatic carcinoma from the thyroid.

[MeSH-major] Adenocarcinoma, Follicular / pathology. Kidney Neoplasms / pathology. Neoplasms, Glandular and Epithelial / pathology

MedlinePlus Health Information. consumer health - Kidney Cancer.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19047894.001).

[ISSN] 1532-0979

[Journal-full-title] The American journal of surgical pathology

[ISO-abbreviation] Am. J. Surg. Pathol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Impact of the 2009 American Thyroid Association guidelines on the choice of operation for well-differentiated thyroid microcarcinomas.

BACKGROUND: The 2009 ATA Guidelines state "lobectomy alone may be sufficient treatment for small (< 1 cm), low risk, unifocal, intrathyroidal papillary carcinomas in the absence of . . . nodal metastases."

METHODS: Medical records of 346 patients with well-differentiated thyroid cancer (WDTC) who underwent thyroidectomy from January 1, 2007 to November 10, 2009, were reviewed.

All but 2 patients had papillary cancer.

CONCLUSION: We recommend that total thyroidectomy be considered as the initial operation for thyroid tumors 6-10 mm in size in which the preoperative FNAB is diagnostic or suspicious for WDTC.

[MeSH-major] Adenocarcinoma, Follicular / surgery. Practice Guidelines as Topic. Thyroid Neoplasms / surgery. Thyroidectomy / methods

[MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biopsy, Fine-Needle / methods. Diagnosis, Differential. Female. Functional Laterality. Humans. Lymph Nodes / pathology. Male. Middle Aged. Neoplasm Invasiveness / pathology. Preoperative Period. Retrospective Studies

MedlinePlus Health Information. consumer health - Thyroid Cancer.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright © 2010 Mosby, Inc. All rights reserved.

(PMID = 21134555.001).

[ISSN] 1532-7361

[Journal-full-title] Surgery

[ISO-abbreviation] Surgery

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Flow pattern and vascular resistive index as predictors of malignancy risk in thyroid follicular neoplasms.

OBJECTIVES: The purpose of this study was to evaluate whether flow pattern and resistive index (RI) are useful parameters for distinguishing benign from malignant thyroid follicular neoplasms (FNs).

METHODS: Eighty-six thyroid nodules that underwent sonographically guided fine-needle aspiration and were diagnosed as cases of FN were evaluated by power and duplex Doppler sonography.

RESULTS: Ten nodules (11.63%) were malignant (3 follicular carcinomas, 5 follicular variants of papillary carcinoma, and 2 papillary carcinomas).

The average RI in non-neoplastic nodules was 0.588 (P < .001, chi(2) test): 0.662 in adenomas and 0.763 in malignant nodules.

None of the nodules had flow pattern type 0.

Flow patterns 1 and 2 (peripheral flow only or predominantly) were present in 58 non-neoplastic nodules (93.5%), 10 adenomas (71.4%), and 2 malignant nodules (20%).

Flow pattern type 3 (predominantly central flow) was present in 7 malignant nodules (70%), 4 adenomas (28.6%), and 4 non-neoplastic nodules (6.5%).

Only 1 nodule, a papillary carcinoma, had flow pattern type 4 (internal flow only).

CONCLUSIONS: In FNs, there were significant positive associations between predominantly central flow and malignancy and between predominantly peripheral flow and benign disease (P < .0001, Fisher exact test).

However, power Doppler characteristics could not be used to rule out malignancy because 20% of malignant nodules had predominantly peripheral flow.

Resistive index values in non-neoplastic nodules were lower than in adenomas and malignant nodules (P < .001, chi(2) test).

[MeSH-major] Adenoma / blood supply. Adenoma / diagnosis. Carcinoma / blood supply. Carcinoma / diagnosis. Thyroid Neoplasms / blood supply. Thyroid Neoplasms / diagnosis. Vascular Resistance

[MeSH-minor] Humans. Predictive Value of Tests. Regional Blood Flow. Reproducibility of Results. Risk Factors. Sensitivity and Specificity. Statistics, Nonparametric. Thyroid Nodule / blood supply. Thyroid Nodule / ultrasonography. Ultrasonography, Doppler, Color / methods. Ultrasonography, Doppler, Duplex / methods

MedlinePlus Health Information. consumer health - Thyroid Cancer.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15972703.001).

[ISSN] 0278-4297

[Journal-full-title] Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine

[ISO-abbreviation] J Ultrasound Med

[Language] eng

[Publication-type] Clinical Trial; Journal Article

[Publication-country] United States

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Prognostic factors of recurrence in encapsulated Hurthle cell carcinoma of the thyroid gland: a clinicopathologic study of 50 cases.

BACKGROUND: Follicular carcinomas of the thyroid gland, including its oncocytic variant (so-called Hurthle cell carcinoma), are subdivided into the indolent encapsulated ("minimally invasive") and the clinically aggressive widely invasive tumors.

There are, however, cases of encapsulated follicular carcinoma that recur and metastasize.

Identifying these cases at the time of diagnosis is crucial for prognostic and therapeutic considerations.

Because to the authors' knowledge most studies do not focus exclusively on the encapsulated Hurthle cell carcinoma (EHC), the current study attempted to identify predictors of recurrence in EHC.

METHODS: A tumor was defined as EHC if it was encapsulated, macroscopically well defined with microscopic but no macroscopic evidence of vascular or capsular invasion, and composed of > 75% follicular oncocytic cells.

Retrospective chart review and microscopic examination identified 50 primary tumors meeting the above criteria at the Memorial Sloan-Kettering Cancer Center between 1967 and 2005.

RESULTS: Seven of 50 (14%) patients developed disease recurrence.

The finding of a solid/trabecular growth and mitosis correlated with the presence of numerous foci (> or = 4) of vascular invasion (P = .01 and P = .005, respectively).

[MeSH-major] Adenoma, Oxyphilic / pathology. Adenoma, Oxyphilic / secondary. Neoplasm Recurrence, Local. Thyroid Neoplasms / pathology

MedlinePlus Health Information. consumer health - Thyroid Cancer.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] 2006 American Cancer Society

(PMID = 16534796.001).

[ISSN] 0008-543X

[Journal-full-title] Cancer

[ISO-abbreviation] Cancer

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Familial thyroid carcinoma: a diagnostic algorithm.

Thyroid carcinomas derived from follicular cells are the most common endocrine malignancies, and papillary thyroid carcinoma (PTC) is the most common type.

Although, the majority of papillary and follicular thyroid carcinomas (FTCs) are sporadic, familial forms have been described in recent years.

Familial syndromes are classified into familial medullary thyroid carcinoma and familial nonmedullary thyroid carcinoma.

Multifocal papillary carcinoma is the most frequent presentation of familial nonmedullary thyroid carcinoma, and based on clinico-pathologic findings it is divided into 2 groups.

The first includes familial syndromes characterized by a predominance of nonthyroidal tumors, such as familial adenomatous polyposis, PTEN-hamartoma tumor syndrome, Carney complex type 1, and Werner syndrome.

The second group includes familial syndromes characterized by a predominance of NMTC, such as pure familial (f) PTC with or without oxyphilia, fPTC with papillary renal cell carcinoma, and fPTC with multinodular goiter.

Medullary thyroid carcinoma is derived from calcitonin-producing C cells.

The familial form accounts for 20% to 25% of cases, and is usually a component of multiple endocrine neoplasia (MEN) IIA or IIB, or presents as pure familial medullary thyroid carcinoma syndrome.

C-cell hyperplasia is the precursor lesion of these heritable syndromes.

Some characteristic morphologic findings should alert the pathologist of a possible familial cancer syndrome, which may lead to further molecular genetic evaluation.

[MeSH-major] Thyroid Neoplasms / diagnosis

[MeSH-minor] Adenomatous Polyposis Coli / genetics. Adenomatous Polyposis Coli / pathology. Adult. Algorithms. Carcinoma, Medullary / diagnosis. Carcinoma, Medullary / genetics. Carcinoma, Medullary / pathology. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / genetics. Carcinoma, Papillary, Follicular / diagnosis. Carcinoma, Papillary, Follicular / genetics. Female. Hamartoma Syndrome, Multiple / pathology. Humans. Middle Aged. Multiple Endocrine Neoplasia Type 2a / pathology. Neoplastic Syndromes, Hereditary / diagnosis. Neoplastic Syndromes, Hereditary / genetics. PTEN Phosphohydrolase / genetics

MedlinePlus Health Information. consumer health - Thyroid Cancer.

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18948764.001).

[ISSN] 1533-4031

[Journal-full-title] Advances in anatomic pathology

[ISO-abbreviation] Adv Anat Pathol

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

[Chemical-registry-number] EC 3.1.3.67 / PTEN Phosphohydrolase

[Number-of-references] 94

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Compurerized morphometric study of thyroid follicular carcinoma in correlation with known prognostic factors.

This study investigates the correlation between computer-assisted nuclear morphometry and known prognostic factors in thyroid follicular carcinoma.

Thirty-six patients with thyroid follicular carcinoma who underwent surgery between 1991 and 2001 were grouped according to sex, age, size of the primary lesion, the presence of vascular invasion, and metastases.

[MeSH-major] Adenocarcinoma, Follicular / pathology. Thyroid Neoplasms / pathology

[MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cell Nucleus / pathology. Diagnosis, Computer-Assisted. Female. Humans. Male. Middle Aged. Prognosis

MedlinePlus Health Information. consumer health - Thyroid Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15825691.001).

[ISSN] 1607-551X

[Journal-full-title] The Kaohsiung journal of medical sciences

[ISO-abbreviation] Kaohsiung J. Med. Sci.

[Language] eng

[Publication-type] Journal Article

[Publication-country] China (Republic : 1949- )

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Charcoal suspension tattoo localization for differentiated thyroid cancer recurrence.

BACKGROUND: The high sensitivity of ultrasound and thyroglobulin determination for follow-up of differentiated thyroid cancer allows early detection of nonpalpable recurrences.

METHODS: Prospective study of 15 consecutive patients with suspected recurrence of differentiated carcinoma.

RESULTS: The injection was well tolerated.

Surgery removed 18 lesions (95%) in 14 patients (93%): carcinoma (16), benign lymphadenitis (2).

CONCLUSIONS: Ultrasound-guided charcoal tattooing is safe, easy, and well-tolerated for localization of nonpalpable lesions in previously operated necks, with a high rate of success.

[MeSH-major] Adenocarcinoma, Follicular / diagnosis. Carcinoma, Papillary / diagnosis. Cell Differentiation. Charcoal. Neoplasm Recurrence, Local / diagnosis. Thyroid Neoplasms / diagnosis

Genetic Alliance. consumer health - Thyroid Cancer.

MedlinePlus Health Information. consumer health - Thyroid Cancer.

Hazardous Substances Data Bank. ACTIVATED CHARCOAL .

Hazardous Substances Data Bank. THYROGLOBULIN .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19551443.001).

[ISSN] 1534-4681

[Journal-full-title] Annals of surgical oncology

[ISO-abbreviation] Ann. Surg. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Iodine Radioisotopes; 16291-96-6 / Charcoal; 9010-34-8 / Thyroglobulin

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] From Mount Sinai to Mount Scopus: differences in the role and value of fine needle aspiration for evaluating thyroid nodules.

BACKGROUND: Fine needle aspiration is the main diagnostic tool used to assess thyroid nodules.

Results compared FNA diagnosis, histological findings and frozen section results (Mt. Sinai only).

"Follicular lesion" was diagnosed on FNA in 33.1% of the patients at Hadassah and in 21.5% at Mt Sinai (P < 0.005) with a malignancy rate of 42.5 vs. 23.1% (P < 0.05), respectively.

Follicular carcinoma was diagnosed in 12 patients at Hadassah vs. 2 patients at Mt.

Follicular lesions and the rate of malignancy in such lesions were more common at Hadassah, favoring a more aggressive surgical approach.

[MeSH-major] Biopsy, Fine-Needle. Thyroid Nodule / pathology

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19637507.001).

[ISSN] 1565-1088

[Journal-full-title] The Israel Medical Association journal : IMAJ

[ISO-abbreviation] Isr. Med. Assoc. J.

[Language] eng

[Publication-type] Comparative Study; Journal Article

[Publication-country] Israel

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Utility of malignancy markers in fine-needle aspiration cytology of thyroid nodules: comparison of Hector Battifora mesothelial antigen-1, thyroid peroxidase and dipeptidyl aminopeptidase IV.

The purpose of this study was to compare the diagnostic interest of Hector Battifora mesothelial antigen-1 (HBME-1), thyroid peroxidase (TPO), and dipeptidyl aminopeptidase IV (DPP4) in thyroid fine-needle aspirates obtained from 200 resected thyroid lesions (55 colloid nodules, 54 follicular adenomas, 59 papillary cancers, and 32 follicular carcinomas).

Receiver operating characteristic (ROC) curves were plotted and optimal cutoff values for diagnosing malignancy were determined.

The TPO ROC curve was consistently higher than the HBME-1 ROC curve.

The TPO curve was also higher than the DPP4 curve with regard to sensitivity, but dipped below the DPP4 curve with regard to specificity.

Due to poor performance on follicular lesions, HBME-1 showed no advantage over TPO or DPP4.

[MeSH-major] Adenocarcinoma, Follicular / metabolism. Autoantigens / metabolism. Biomarkers, Tumor / metabolism. Carcinoma, Papillary / metabolism. Dipeptidyl Peptidase 4 / metabolism. Iodide Peroxidase / metabolism. Iron-Binding Proteins / metabolism. Thyroid Neoplasms / metabolism

[MeSH-minor] Biopsy, Fine-Needle. Biopsy, Needle. Cytodiagnosis. Humans. Immunoenzyme Techniques. ROC Curve. Sensitivity and Specificity. Thyroid Nodule / metabolism. Thyroid Nodule / pathology

MedlinePlus Health Information. consumer health - Thyroid Cancer.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Mod Pathol. 2005 Apr;18(4):541-6 [15529186.001]

[Cites] Eur J Endocrinol. 1994 Nov;131(5):474-9 [7952158.001]

[Cites] Cancer. 2005 Apr 25;105(2):87-95 [15742329.001]

[Cites] Endocr Relat Cancer. 2005 Jun;12(2):305-17 [15947105.001]

[Cites] Thyroid. 2006 Feb;16(2):109-42 [16420177.001]

[Cites] J Clin Endocrinol Metab. 2006 May;91(5):1934-42 [16407496.001]

[Cites] Am J Clin Pathol. 2006 Jun;125(6):873-82 [16690487.001]

[Cites] Histopathology. 2006 Jun;48(7):795-800 [16722927.001]

[Cites] Endocr Relat Cancer. 2006 Jun;13(2):485-95 [16728576.001]

[Cites] J Mol Diagn. 2006 Sep;8(4):490-8; quiz 528 [16931590.001]

[Cites] Adv Anat Pathol. 2006 Sep;13(5):228-37 [16998316.001]

[Cites] Am J Clin Pathol. 2006 Nov;126(5):700-8 [17050067.001]

[Cites] J Clin Oncol. 2006 Nov 1;24(31):5043-51 [17075124.001]

[Cites] Virchows Arch. 2007 Mar;450(3):249-60 [17252232.001]

[Cites] Surgery. 1999 Dec;126(6):1200-4 [10598208.001]

[Cites] Surgery. 1994 Dec;116(6):1031-5 [7985083.001]

[Cites] Virchows Arch. 1996 Nov;429(4-5):213-9 [8972756.001]

[Cites] Ann Pathol. 1996 Sep;16(4):261-5 [9172614.001]

[Cites] Mod Pathol. 1997 Jul;10(7):668-74 [9237176.001]

[Cites] Diagn Cytopathol. 1998 Feb;18(2):93-7 [9484636.001]

[Cites] Pathol Res Pract. 1997;193(10):705-12 [9505263.001]

[Cites] Eur J Endocrinol. 2004 Dec;151(6):779-86 [15588246.001]

[Cites] Mod Pathol. 2005 Jan;18(1):48-57 [15272279.001]

[Cites] Thyroid. 2000 Feb;10(2):109-15 [10718546.001]

[Cites] Clin Endocrinol (Oxf). 2000 Aug;53(2):161-9 [10931096.001]

[Cites] Mod Pathol. 2001 Apr;14(4):338-42 [11301350.001]

[Cites] Diagn Cytopathol. 2002 Jan;26(1):41-4 [11782086.001]

[Cites] Histopathology. 2002 Feb;40(2):133-42 [11952857.001]

[Cites] Radiology. 1982 Apr;143(1):29-36 [7063747.001]

[Cites] Cancer. 1991 Jun 15;67(12):3036-41 [1710535.001]

[Cites] Am J Clin Pathol. 1991 Sep;96(3):306-10 [1715126.001]

[Cites] JAMA. 1994 Mar 2;271(9):703-7 [8309035.001]

[Cites] Anticancer Res. 2005 Jan-Feb;25(1A):179-82 [15816536.001]

(PMID = 18212751.001).

[ISSN] 0007-0920

[Journal-full-title] British journal of cancer

[ISO-abbreviation] Br. J. Cancer

[Language] eng

[Publication-type] Comparative Study; Journal Article

[Publication-country] England

[Chemical-registry-number] 0 / Autoantigens; 0 / Biomarkers, Tumor; 0 / HBME-1 antigen; 0 / Iron-Binding Proteins; EC 1.11.1.7 / TPO protein, human; EC 1.11.1.8 / Iodide Peroxidase; EC 3.4.14.5 / DPP4 protein, human; EC 3.4.14.5 / Dipeptidyl Peptidase 4

[Other-IDs] NLM/ PMC2259194

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Reoperation for recurrent/persistent well-differentiated thyroid cancer.

Reoperative surgery in the neck for recurrent/persistent well-differentiated thyroid cancer is associated with increased morbidity compared with primary surgery.

When performing reoperative surgery, an algorithm should be followed that allows for safe and effective removal of recurrent/persistent disease.

This algorithm should include a systematic review of prior operative and pathology notes, imaging studies appropriate for localization of disease, an understanding of reoperative central and lateral neck anatomy, along with an appreciation for disease behavior.

[MeSH-major] Adenocarcinoma, Follicular / surgery. Carcinoma, Medullary / surgery. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Neoplasm, Residual / surgery. Thyroid Neoplasms / pathology. Thyroid Neoplasms / surgery

Genetic Alliance. consumer health - Thyroid Cancer.

MedlinePlus Health Information. consumer health - Thyroid Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright 2010 Elsevier Inc. All rights reserved.

(PMID = 20510718.001).

[ISSN] 1557-8259

[Journal-full-title] Otolaryngologic clinics of North America

[ISO-abbreviation] Otolaryngol. Clin. North Am.

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

[Number-of-references] 46

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Radioiodine thyroid remnant ablation in patients with differentiated thyroid carcinoma (DTC): prospective comparison of long-term outcomes of treatment with 30, 60 and 100 mCi.

BACKGROUND: The aim of this study is to compare the effectiveness of 131I therapy between three groups of DTC patients who received 30, 60 or 100 mCi for thyroid remnant ablation after total thyroidectomy and were postoperatively judged with low risk of cancer recurrence.

The present study comprises the long-term assessment of the disease course in 3 study groups.

RESULTS: A group of 309 DTC patients (285 women and 24 men) with no clinical, histopathological, sonographical or biochemical signs of persistent disease were included after total thyroidectomy and appropriate extent of neck lymph node dissection (265 with papillary and 44 with follicular thyroid cancer).

For radioiodine thyroid remnant ablation, 30 mCi of 131I was applied in 86 patients, whereas 60 mCi in 128 and 100 mCi in 95 patients.

In the first evaluation, published previously, we observed that because of incomplete thyroid remnant ablation, the second 131I treatment was necessary in 10% patients, without difference between groups treated with 60 and 100 mCi and in 22% patients treated with 30 mCi.

To evaluate the long-term outcome of the adjuvant 131I treatment, the course of the follow-up and the most recent disease status were assessed by sonography, radiological examinations and serum Tg estimation (on LT4-suppressive treatment).

CONCLUSIONS: No significant differences in the 5 years efficacy of thyroid remnant radioiodine ablation using 30, 60 and 100 mCi were observed in low-risk DTC patients operated by total thyroidectomy and neck lymph node dissection.

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 21040579.001).

[ISSN] 1756-6614

[Journal-full-title] Thyroid research

[ISO-abbreviation] Thyroid Res

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

[Other-IDs] NLM/ PMC2989933

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Comparison of outcomes after (123)I versus (131)I pre-ablation imaging before radioiodine ablation in differentiated thyroid carcinoma.

Detection of residual tissue after thyroidectomy for papillary or follicular thyroid carcinoma may be performed using diagnostic imaging with either (123)I or (131)I.

The former is often preferred to avoid "stunning"-defined as a reduction in uptake of the therapeutic dose of (131)I caused by some form of cell damage from the diagnostic dosage of the radionuclide.

This study examines the outcomes of ablative (131)I therapy after diagnostic studies with either (123)I or (131)I to determine if the diagnostic dosages of these radionuclides used in our Thyroid Cancer Center reduce the efficacy of (131)I given for remnant ablation.

METHODS: Fifty patients with nonmetastatic papillary or follicular carcinoma of the thyroid received total thyroidectomy; this was followed by thyroid hormone withdrawal to achieve a serum thyroid-stimulating hormone level in excess of 30 microIU/mL.

Group 1 had diagnostic imaging with 14.8 MBq of (123)I followed by thyroid remnant ablation with 3.7 GBq of (131)I.

Successful ablation required a negative follow-up thyroid scan 6-8 mo after ablation and also an undetectable serum thyroglobulin level in the absence of antithyroglobulin antibodies.

CONCLUSION: If thyroid remnant stunning occurs due to 74 MBq (131)I used as a diagnostic agent before (131)I ablation, it has no significant clinical correlate, as it yields the same ablation rate as that which occurs after 14.8 MBq of (123)I used for imaging.

[MeSH-major] Adenocarcinoma, Follicular / radionuclide imaging. Carcinoma, Papillary / radionuclide imaging. Iodine Radioisotopes / therapeutic use. Radiopharmaceuticals / therapeutic use. Thyroid Neoplasms / radionuclide imaging

[MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Thyroid Hormones / blood. Thyroidectomy. Treatment Outcome

MedlinePlus Health Information. consumer health - Thyroid Cancer.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentIn] J Nucl Med. 2008 Jan;49(1):166; author reply 166-7 [18165699.001]

(PMID = 17574976.001).

[ISSN] 0161-5505

[Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine

[ISO-abbreviation] J. Nucl. Med.

[Language] eng

[Publication-type] Comparative Study; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Iodine Radioisotopes; 0 / Radiopharmaceuticals; 0 / Thyroid Hormones

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] A rare case of skull base metastasis from follicular carcinoma of thyroid.

We are reporting a case of skull base metastasis from follicular carcinoma of thyroid in an adult lady.

She presented with the history of a longstanding thyroid swelling and recent onset epistaxis and diplopia.

She was evaluated and diagnosed to have follicular carcinoma of thyroid with metastasis to the skull base.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 22693385.001).

[ISSN] 0976-6952

[Journal-full-title] Indian journal of surgical oncology

[ISO-abbreviation] Indian J Surg Oncol

[Language] eng

[Publication-type] Journal Article

[Publication-country] India

[Other-IDs] NLM/ PMC3244260

[Keywords] NOTNLM ; Follicular carcinoma / Metastasis / Skull base / Thyroid

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Incidental parathyroid adenoma mimicking tumor recurrence in a patient with follicular thyroid carcinoma.

We report the case of a 59-year-old woman with a history of follicular thyroid cancer who had reoperation for suspected local tumor recurrence as laboratory (tumor marker), imaging findings (ultrasound, I-131 scintigraphy and Tc-99m-MIBI scintigraphy), and also fine needle aspiration (FNA) cytology were equivocal.

[MeSH-major] Adenocarcinoma, Follicular / radionuclide imaging. Adenoma / radionuclide imaging. Neoplasm Recurrence, Local / radionuclide imaging. Parathyroid Neoplasms / radionuclide imaging. Thyroid Neoplasms / radionuclide imaging

[MeSH-minor] Diagnosis, Differential. Female. Humans. Incidental Findings. Middle Aged

Genetic Alliance. consumer health - Parathyroid carcinoma.

MedlinePlus Health Information. consumer health - Thyroid Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16424689.001).

[ISSN] 0363-9762

[Journal-full-title] Clinical nuclear medicine

[ISO-abbreviation] Clin Nucl Med

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] High frequency of somatic mitochondrial DNA mutations in human thyroid carcinomas and complex I respiratory defect in thyroid cancer cell lines.

Significant progress has been made to elucidate the molecular mechanisms that determine thyroid tumor development and progression.

The potential role of mitochondrial DNA (mtDNA) mutations in thyroid tumorigenesis is not well defined.

In the present study, we investigated the frequency of mtDNA mutations in 24 thyroid tumor specimens (19 primary papillary thyroid carcinomas (PTC), one follicular thyroid carcinoma, and four multinodular hyperplasias) and four thyroid cancer cell lines by sequencing the entire coding regions of mitochondrial genome.

All the thyroid tumor cell lines carried sequence variations that change amino acid and have not been reported previously as normal sequence variants.

Flow cytometry analysis of mitochondria respiratory function in the thyroid tumor cell lines revealed a severe defect in mitochondrial complex I activity.

The mutations were either A --> G or C --> T transitions, often resulting in a change of a moderately or highly conserved amino acid of their corresponding protein.

These data suggest that mtDNA mutations may play an important role in the thyroid tumorigenesis.

[MeSH-major] Carcinoma / genetics. DNA, Mitochondrial / genetics. Electron Transport Complex I / physiology. Mutation / genetics. Thyroid Neoplasms / genetics

[MeSH-minor] Cell Line, Tumor. Humans. Neoplasm Staging

Genetic Alliance. consumer health - Thyroid Cancer.

MedlinePlus Health Information. consumer health - Thyroid Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15608681.001).

[ISSN] 0950-9232

[Journal-full-title] Oncogene

[ISO-abbreviation] Oncogene

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

[Chemical-registry-number] 0 / DNA, Mitochondrial; EC 1.6.5.3 / Electron Transport Complex I

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Sixteen of these foci of increased uptake were hyperplastic parathyroid glands, six were adenomas, one was a parathyroid carcinoma and one was a thyroid follicular carcinoma.

CONCLUSIONS: We believe 99mTc-sestamibi SPECT/CT to be a more reliable presurgical method to study a patient subgroup affected by PHP or SHP in whom conventional US and other scintigraphic methods have failed for intrinsic reasons due to the concomitant presence of multinodular goitre or ectopic parathyroid gland.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17021682.001).

[ISSN] 0033-8362

[Journal-full-title] La Radiologia medica

[ISO-abbreviation] Radiol Med

[Language] eng; ita

[Publication-type] Comparative Study; Journal Article

[Publication-country] Italy

[Chemical-registry-number] 0 / Radiopharmaceuticals; 971Z4W1S09 / Technetium Tc 99m Sestamibi

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Treatment of microcarcinoma and papillary carcinoma of the thyroid].

[Transliterated title] Trattamento del microcarcinoma e del carcinoma papillifero della tiroide.

AIM OF THE STUDY: Of our is to demonstrate that total thyroidectomy with lymphadenectomy of the six level is effective in papillary thyroid carcinomas than for microcarcinoma, according to recent acquisitions on the biological behavior of some microcarcinoma.

RESULTS: Of all the interventions of total thyroidectomy, 75% performed for benign disease and 25% for malignant disease (PTMC 356 cases, 291 PTC cases, 56 cases of follicular carcinoma, 5 cases of medullary carcinoma, anaplastic carcinoma, 2 cases).

40% of PTMC underwent TT and subsequent follow up, because the diagnosis was placed postoperatively and in 60% diagnosis was placed during surgery with indication for TT and lymphadenectomy of the sixth level and subsequent follow-up showed no evidence of residual disease or relapse.

All patients in the follow-up post-operatively does not show in the following years, signs of residual disease or relapse.

This applies to papillary carcinomas than for microcarcinoma whose surgical treatment (total thyroidectomy, lobectomy, subtotal thyroidectomy or near-total) is still debated.

[MeSH-major] Carcinoma, Papillary / surgery. Lymph Node Excision. Thyroid Neoplasms / surgery. Thyroidectomy

MedlinePlus Health Information. consumer health - Thyroid Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20726389.001).

[ISSN] 0003-469X

[Journal-full-title] Annali italiani di chirurgia

[ISO-abbreviation] Ann Ital Chir

[Language] ita

[Publication-type] English Abstract; Journal Article

[Publication-country] Italy

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Carcinoma thyroid in multi and uninodular goiter.

OBJECTIVE: To determine the frequency and profile of carcinoma in multi-nodular goiter and solitary thyroid nodule.

METHODOLOGY: Cases with solitary thyroid nodules and multi-nodular goiter were included.

Patients under 12 years of age, cystic benign lesion in solitary thyroid nodules or those multi-nodular goiters which were not causing pressure symptoms, cosmetic problems or sign of malignancy were excluded.

In solitary thyroid nodule, hemithyroidectomy was done and if histopathology examination revealed carcinoma thyroid then completion thyroidectomy was done.

Results were described as frequency percentages and mean.

RESULTS: Out of 397 patients of multi-nodular goiter only one patient was found to be papillary carcinoma (0.25%).

In 220 patients of solitary thyroid nodules, 93 patients were diagnosed as carcinoma of thyroid (42.27%).

Others diagnosed in solitary thyroid nodule were thyroid adenoma, colloid goiter, thyroiditis and multi-nodular goiter.

The frequency of papillary carcinoma in 65.95% occuring females of 12-30 years of age and being multifocal in 6.45%, follicular carcinoma in 23.40%, medullary carcinoma in 7.44%, anaplastic carcinoma in 2.12% and lymphoma in 1.01%.

Female were predominantly involved and papillary carcinoma was common in 12-30 years of age (71.63%) and follicular was common in 30-40 years of age (68.18%).

6.45% of papillary carcinoma was found to be multifocal in nature.

CONCLUSION: Frequency of carcinoma of thyroid is very high in solitary thyroid nodule (42.27%), but markedly low in multinodular goiter.

Papillary carcinoma is the most common variety, most of in younger female.

[MeSH-major] Carcinoma / epidemiology. Carcinoma / pathology. Goiter, Nodular / pathology. Thyroid Nodule / epidemiology. Thyroid Nodule / pathology

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20642922.001).

[ISSN] 1022-386X

[Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP

[ISO-abbreviation] J Coll Physicians Surg Pak

[Language] eng

[Publication-type] Journal Article

[Publication-country] Pakistan

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Endogenous avidin biotin activity (EABA) in thyroid pathology: immunohistochemical study.

The aim of our investigation is to study presence of endogenous avidin biotin activity (EABA) in thyrocytes originating from various thyroid pathological lesions (neoplastic and non-neoplastic).

MATERIALS AND METHODS: The immunohistochemical study was performed on paraffin-embedded specimens of surgically resected thyroid tissue from 97 patients with thyroid diseases: 65 patients with papillary carcinoma (PTC), 11 patients with nodular goiter in whom features of benign papillary hyperplasia were found, 9 with lymphocytic thyroiditis (LT), 8 with follicular adenoma, and 4 patients with follicular carcinoma.

Normal surrounding thyroid tissues showed absence or weak EABA.

CONCLUSION: Among thyroid lesions, false positive reactions are highly probable in papillary thyroid carcinoma and in lymphocytic thyroiditis if immunohistochemical detection is used on systems containing (strept)avidin.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Biochemistry. 1999 Apr 6;38(14):4252-8 [10194342.001]

[Cites] Histopathology. 1997 Nov;31(5):400-7 [9416479.001]

[Cites] Zhonghua Bing Li Xue Za Zhi. 2002 Dec;31(6):491-6 [12622897.001]

[Cites] Biochem Biophys Res Commun. 1998 Jun 18;247(2):312-4 [9642122.001]

[Cites] Histochemistry. 1985;83(4):325-30 [2415495.001]

[Cites] J Histochem Cytochem. 1981 Oct;29(10):1196-204 [7028859.001]

[Cites] Arch Med Res. 2002 Sep-Oct;33(5):439-47 [12459313.001]

[Cites] J Nutr Biochem. 2005 Jul;16(7):441-5 [15992688.001]

[Cites] Clin Chim Acta. 1996 Nov 15;255(1):1-11 [8930409.001]

[Cites] Arch Pathol Lab Med. 2002 Jun;126(6):710-3 [12033961.001]

[Cites] Hum Pathol. 2006 Dec;37(12):1592-600 [16949643.001]

[Cites] J Nutr Biochem. 2005 Jul;16(7):432-4 [15992685.001]

[Cites] J Clin Pathol. 1984 Feb;37(2):223-5 [6198343.001]

[Cites] Mod Pathol. 1997 May;10(5):515-9 [9160320.001]

[Cites] Histopathology. 2002 Oct;41(4):357-62 [12383219.001]

[Cites] Histochem J. 2002 Mar-Apr;34(3-4):97-103 [12495214.001]

[Cites] J Nutr Biochem. 2005 Jul;16(7):419-23 [15992682.001]

[Cites] Am J Vet Res. 1993 Jul;54(7):1177-82 [8368617.001]

[Cites] J Nutr. 2001 Jul;131(7):1909-13 [11435506.001]

(PMID = 19351422.001).

[ISSN] 1756-6614

[Journal-full-title] Thyroid research

[ISO-abbreviation] Thyroid Res

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

[Other-IDs] NLM/ PMC2678080

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Gene profiling identifies genes specific for well-differentiated epithelial thyroid tumors.

Thyroid nodules are common.

To that end we have studied gene profiles of 5 types of benign and malignant thyroid nodular tissue (multinodular goiter, follicular adenoma, papillary and follicular carcinomas).

Despite the differences in the microarray panels used, we confirmed the differential regulation of 12 genes previously reported in thyroid cancer, although we found the expression of several genes to be regulated in other histological tumor subtypes than originally described.

We found, PCSK2, TRIB1, RAP1 GA1 to be specifically overexpressed in follicular cancer and S100A4 and GK2 in papillary carcinoma.

SERP1, RNASE 2 and STATA5 were suppressed in papillary thyroid cancer.

We have thus identified new potential markers specific to malignant thyroid tumors.

It is apparent that a range of nodular thyroid tissue using large tumor sample numbers is necessary to establish robust markers for malignancy and to categorize tumors on the basis of small tumor samples.

[MeSH-major] Gene Expression Profiling. Genes, Neoplasm. Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / genetics

[MeSH-minor] Adenocarcinoma, Follicular / diagnosis. Adenocarcinoma, Follicular / genetics. Adenocarcinoma, Follicular / physiopathology. Adenoma / diagnosis. Adenoma / genetics. Adenoma / physiopathology. Biomarkers, Tumor / genetics. Biopsy, Fine-Needle. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / genetics. Carcinoma, Papillary / physiopathology. Gene Expression Regulation, Neoplastic. Goiter, Nodular / diagnosis. Goiter, Nodular / genetics. Goiter, Nodular / physiopathology. Humans. Microscopy, Confocal. Oligonucleotide Array Sequence Analysis. Polymerase Chain Reaction

MedlinePlus Health Information. consumer health - Thyroid Cancer.

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16171553.001).

[ISSN] 1165-158X

[Journal-full-title] Cellular and molecular biology (Noisy-le-Grand, France)

[ISO-abbreviation] Cell. Mol. Biol. (Noisy-le-grand)

[Language] eng

[Publication-type] Journal Article

[Publication-country] France

[Chemical-registry-number] 0 / Biomarkers, Tumor

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Pendred syndrome is an autosomal recessive disorder characterized by congenital sensorineural deafness, goiter, and impaired iodide organification.

Follicular thyroid carcinoma and Hürthle cell adenoma were found in affected members of a family, raising the possibility of an increased risk of thyroid carcinoma in Pendred syndrome patients.

The identification of these two frequent PDS mutations will facilitate the molecular diagnosis of Pendred syndrome in Thai populations.

[MeSH-minor] Adenoma, Oxyphilic / genetics. Adult. Alleles. Female. Humans. Iodides / metabolism. Male. Middle Aged. Pedigree. Risk Factors. Syndrome. Thailand. Thyroid Neoplasms / genetics

Genetic Alliance. consumer health - Pendred syndrome.

MedlinePlus Health Information. consumer health - Hearing Disorders and Deafness.

MedlinePlus Health Information. consumer health - Hypothyroidism.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Proc Natl Acad Sci U S A. 2001 Mar 27;98(7):4221-6 [11274445.001]

[Cites] J Med Genet. 2003 Apr;40(4):242-8 [12676893.001]

[Cites] Laryngoscope. 2006 Nov;116(11):2027-36 [17075407.001]

[Cites] J Clin Endocrinol Metab. 1998 Nov;83(11):4162-6 [9814507.001]

[Cites] Acta Otolaryngol. 2000 Mar;120(2):137-41 [11603758.001]

[Cites] Hum Genet. 1999 Feb;104(2):188-92 [10190331.001]

[Cites] Clin Endocrinol Metab. 1981 Jul;10(2):317-35 [7285382.001]

[Cites] J Clin Endocrinol Metab. 2000 May;85(5):2028-33 [10843192.001]

[Cites] Hum Mol Genet. 1998 Jul;7(7):1099-104 [9618166.001]

[Cites] J Clin Endocrinol Metab. 2006 Jul;91(7):2678-81 [16684826.001]

[Cites] Nat Genet. 1997 Dec;17(4):411-22 [9398842.001]

[Cites] Eur Arch Otorhinolaryngol. 2006 Aug;263(8):699-704 [16703388.001]

[Cites] Hum Mutat. 1998;11(1):1-3 [9450896.001]

[Cites] Hum Mutat. 2001 May;17(5):403-11 [11317356.001]

[Cites] J Med Genet. 1999 Jun;36(6):475-7 [10874637.001]

[Cites] Thyroid. 2001 Oct;11(10):981-8 [11716048.001]

[Cites] Am J Physiol Renal Physiol. 2001 Feb;280(2):F356-64 [11208611.001]

[Cites] Endocrinology. 2000 Feb;141(2):839-45 [10650967.001]

[Cites] Clin Radiol. 1998 Apr;53(4):268-73 [9585042.001]

[Cites] J Clin Endocrinol Metab. 2002 Feb;87(2):938 [11836344.001]

[Cites] Am J Med Genet A. 2004 Jan 1;124A(1):1-9 [14679580.001]

[Cites] J Biol Chem. 2004 Mar 26;279(13):13004-10 [14715652.001]

[Cites] J Clin Endocrinol Metab. 2002 Jul;87(7):3356-61 [12107249.001]

[Cites] Hum Mol Genet. 1998 Jul;7(7):1105-12 [9618167.001]

[Cites] Eur J Hum Genet. 2006 Jun;14 (6):773-9 [16570074.001]

[Cites] J Clin Endocrinol Metab. 2000 Nov;85(11):4367-72 [11095481.001]

[Cites] Proc Natl Acad Sci U S A. 1999 Aug 17;96(17):9727-32 [10449762.001]

[Cites] Hum Mol Genet. 2000 Jul 1;9(11):1709-15 [10861298.001]

[Cites] Eur J Hum Genet. 2003 Dec;11(12):916-22 [14508505.001]

[Cites] J Med Genet. 1999 Aug;36(8):595-8 [10465108.001]

[Cites] Cancer. 1991 Apr 15;67(8):2191-3 [2004339.001]

[Cites] Hum Mutat. 2002 Jul;20(1):77-8 [12112665.001]

[Cites] J Clin Endocrinol Metab. 2001 Aug;86(8):3907-11 [11502831.001]

[Cites] Am J Physiol Endocrinol Metab. 2003 Jan;284(1):E25-8 [12388138.001]

(PMID = 18250610.001).

[ISSN] 1720-8386

[Journal-full-title] Journal of endocrinological investigation

[ISO-abbreviation] J. Endocrinol. Invest.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Italy

[Chemical-registry-number] 0 / Iodides; 0 / Membrane Transport Proteins; 0 / SLC26A4 protein, human

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] A rare case of follicular thyroid carcinoma in ovarian struma.

Struma ovarii is a form of specialised mature teratoma, with predominantly mature thyroid tissue in an ovarian teratoma as seen in 2% of cases.

Its malignant transformation is even rarer and is seen in only 5% of those cases.

This 40-year-old female patient had an incidental finding of a pelvic mass during investigation of secondary amenorrhoea.

The histopathology revealed a bilateral mature teratoma of the ovary with follicular thyroid carcinoma in the right ovarian struma (malignant struma).

The patient remains well after four years and is being followed-up with serial serum thyroglobulin surveillance.

[MeSH-major] Adenocarcinoma, Follicular / pathology. Ovarian Neoplasms / pathology. Struma Ovarii / pathology. Thyroid Neoplasms / pathology

MedlinePlus Health Information. consumer health - Ovarian Cancer.

MedlinePlus Health Information. consumer health - Thyroid Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18939380.001).

[ISSN] 1479-666X

[Journal-full-title] The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland

[ISO-abbreviation] Surgeon

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Scotland

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Childhood thyroid carcinoma: clinical analyses of 22 cases].

BACKGROUND & OBJECTIVE: Thyroid carcinoma is rarely occurred in children.

Clinicopathologic characteristics, therapy and prognosis of childhood thyroid carcinoma patients are different from those of adult patients, and the treatment of this disease is controversial.

This study was to explore the clinicopathologic characteristics, diagnosis and therapy of thyroid carcinoma in children.

METHODS: Clinical data of 22 children under the age of 14, diagnosed as thyroid carcinoma between Jan.

Of the 22 patients, 8 (36.4%) had papillary carcinoma, 8 (36.4%) had follicular carcinoma, 5(22.7%) had mixed papillary-follicular carcinoma, and 1 (4.5%) had medullary carcinoma.

CONCLUSIONS: Childhood thyroid carcinomas are mostly differentiated carcinomas, with high frequency of cervical lymph node metastases.

The optimal treatment for thyroid carcinoma in children may improve the quality of life and decrease the incidence of complications.

[MeSH-major] Thyroid Neoplasms / therapy

MedlinePlus Health Information. consumer health - Thyroid Cancer.

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18334124.001).

[Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer

[ISO-abbreviation] Ai Zheng

[Language] chi

[Publication-type] English Abstract; Journal Article

[Publication-country] China

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Cordycepin induces apoptosis of CGTH W-2 thyroid carcinoma cells through the calcium-calpain-caspase 7-PARP pathway.

We used CGTH W-2, a follicular thyroid carcinoma cell line, to study the mechanism of the anticancer effect of cordycepin.

Cordycepin decreased cell viability and resulted in apoptosis but not necrosis.

[MeSH-major] Antineoplastic Agents, Phytogenic / pharmacology. Apoptosis / drug effects. Calcium / metabolism. Calpain / metabolism. Caspase 7 / metabolism. Deoxyadenosines / pharmacology. Poly(ADP-ribose) Polymerases / metabolism. Thyroid Neoplasms / metabolism

[MeSH-minor] Cell Line, Tumor. Cordyceps / chemistry. Gene Expression Regulation, Neoplastic / drug effects. Humans. Signal Transduction / drug effects

MedlinePlus Health Information. consumer health - Thyroid Cancer.

Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20961042.001).

[ISSN] 1520-5118

[Journal-full-title] Journal of agricultural and food chemistry

[ISO-abbreviation] J. Agric. Food Chem.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Deoxyadenosines; 73-03-0 / cordycepin; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases; EC 3.4.22.- / Calpain; EC 3.4.22.- / Caspase 7; SY7Q814VUP / Calcium

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Expression of c-kit, Flk-1, and Flk-2 receptors in benign and malignant tumors of follicular epithelial origin.

BACKGROUND: Vascular endothelial growth factor (VEGF) is a key regulator of physiologic as well as pathologic angiogenesis.

The response of VEGF to endothelial cell mitogenesis and survival, as well as angiogenesis and microvascular permeability, is mainly mediated through its receptor-2, VEGFR2 (kinase domain receptor or fetal liver kinase-1, KDR or Flk-1).

This study aimed to detect the expression of VEGFR2 in various forms of thyroid tumors.

In addition, the expression of Flk-2 (receptor for Flt-3) and c-Kit (receptor for steel locus factor), which shows strong similarity to Flk-1, was also examined in thyroid tumors.

METHODS: RT-PCR analyses of c-Kit and immunohistochemical staining of c-Kit, Flk-1, and Flk-2 were performed in archived samples of 18 papillary thyroid carcinoma (PTC), 9 follicular thyroid carcinoma (FTC), 12 follicular adenoma (FA), and 7 nodular goiter (NG) samples.

RESULTS: By RT-PCR analyses, c-Kit expression was detected in 22% (4/18) of PTC, 22% (2/9) of FTC, 25% (3/12) of FA, and 57% (4/7) of NG samples.

However, positive immunostaining signals of c-Kit were only observed in 17% (3/18) of PTC samples, and not in the others.

Interestingly, the expression of Flk-2 was found in 89% (16/18) of PTC, 89% (8/9) of FTC, 75% (9/12) of FA, and 29% (2/7) of NG samples.

An inverse relationship of thyroid cancer size with Flk-2 expression was found.

CONCLUSION: Flk-2 expression was detected in various forms of thyroid tumors and increased Flk-2 expression was correlated with thyroid tumors with increased transforming activity, suggesting that Flk-2 is involved in pathogenic development of thyroid malignancy.

Similarly, Flk-1 expression was also found in some thyroid tumors, while the expression of c-Kit-mediated pathways may not play a major role in thyroid tumorigenesis.

[MeSH-major] Adenocarcinoma, Follicular / chemistry. Proto-Oncogene Proteins c-kit / analysis. Thyroid Neoplasms / chemistry. Vascular Endothelial Growth Factor Receptor-2 / analysis. fms-Like Tyrosine Kinase 3 / analysis

[MeSH-minor] Adolescent. Adult. Aged. Carcinoma, Papillary / chemistry. Female. Humans. Immunohistochemistry. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction

MedlinePlus Health Information. consumer health - Thyroid Cancer.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16570574.001).

[ISSN] 1726-4901

[Journal-full-title] Journal of the Chinese Medical Association : JCMA

[ISO-abbreviation] J Chin Med Assoc

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] China (Republic : 1949- )

[Chemical-registry-number] EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Prognostic values of thyroid tumours.

Thyroid cancer accounts for approximately 1% of total cancer cases in developed countries.

The aim of this study has been to analyze the histopathological variants of thyroid tumours with regard to gender and age.

During the period from 2001-2007, 138 biopsy cases of thyroid tumours, which were fixed in buffered neutral formalin and embedded in paraffin, have been reviewed.

Follicular adenomas have been found in 39, 1% of cases, thyroid carcinomas in 60, 12%, whereas thyroid secondary carcinomas have been found in 0, 72% of cases.

As far as histological variants of thyroid carcinomas are concerned, most frequently found were papillary carcinomas in 39,85% of cases; followed by follicular carcinomas in 9,42% of cases; follicular variants of papillary carcinomas in 5,79% of cases; medullary carcinomas in 3,62% of cases, while anaplastic and Hurthle cell carcinomas have been found in 0,72% of cases each.

All histological variants of thyroid tumours occurred more frequently in women than in men.

Papillary carcinoma has been found in 80% of female cases.

Thyroid tumours in our material mainly occurred in the third, the fourth and the fifth decade of life.

Our data indicate that apart from the fact that papillary carcinomas, well differentiated, and characterised by relatively good prognosis, were most frequent variants, certain morphological variants of it were associated with poor prognosis.

[MeSH-major] Thyroid Neoplasms / mortality

MedlinePlus Health Information. consumer health - Thyroid Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Endocrinol Invest. 2008 Nov;31(11):1032-7 [19169062.001]

[Cites] Cancer. 1997 Feb 1;79(3):564-73 [9028369.001]

[Cites] Cancer Biother Radiopharm. 2008 Oct;23(5):655-9 [18976119.001]

[Cites] J Clin Endocrinol Metab. 2006 Jun;91(6):2171-8 [16478817.001]

[Cites] Eur J Surg. 1992 Nov-Dec;158(11-12):583-9 [1363062.001]

[Cites] Ann Surg. 2005 Apr;241(4):640-6 [15798466.001]

[Cites] Ann Surg Oncol. 2008 Sep;15(9):2493-9 [18594930.001]

[Cites] Minerva Chir. 2007 Oct;62(5):315-25 [17947943.001]

[Cites] Cancer. 1979 Mar;43(3):810-20 [427722.001]

[Cites] Postgrad Med J. 1999 Mar;75(881):169-70 [10448499.001]

[Cites] BMC Cancer. 2008 Oct 14;8:296 [18851763.001]

[Cites] Vopr Onkol. 2007;53(1):37-45 [17649732.001]

[Cites] Thyroid. 2002 Feb;12(2):163-8 [11916286.001]

[Cites] J Clin Endocrinol Metab. 1997 Nov;82(11):3553-62 [9360506.001]

[Cites] G Chir. 2008 Apr;29(4):152-8 [18419979.001]

[Cites] Endocr J. 2007 Apr;54(2):265-74 [17379963.001]

[Cites] J Surg Oncol. 2007 Dec 1;96(7):598-604 [17708543.001]

[Cites] Lancet. 2003 Feb 8;361(9356):501-11 [12583960.001]

[Cites] Endocr Relat Cancer. 2004 Mar;11(1):131-9 [15027890.001]

[Cites] J Clin Endocrinol Metab. 2001 Apr;86(4):1447-63 [11297567.001]

[Cites] Thyroid. 2007 Sep;17(9):883-8 [17956162.001]

[Cites] Minerva Endocrinol. 2008 Dec;33(4):359-79 [18923371.001]

[Cites] Endocr Regul. 2005 Sep;39(3):73-83 [16468229.001]

[Cites] J Clin Pathol. 2004 Oct;57(10):1041-6 [15452157.001]

[Cites] Ann Surg Oncol. 2008 May;15(5):1518-22 [18324441.001]

[Cites] J Surg Oncol. 2008 Mar 1;97(3):221-5 [18050283.001]

[Cites] Chirurgia (Bucur). 2007 May-Jun;102(3):289-95 [17687857.001]

[Cites] J Clin Endocrinol Metab. 2002 Jun;87(6):2455-9 [12050199.001]

[Cites] Endocr J. 2008 May;55(2):269-75 [18469487.001]

[Cites] Am J Surg Pathol. 1989 Dec;13(12):1041-9 [2490923.001]

[Cites] Surgery. 1998 Dec;124(6):947-57 [9854568.001]

[Cites] Eur Arch Otorhinolaryngol. 2007 Aug;264(8):935-9 [17431661.001]

[Cites] Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2008 Dec;43(12):939-43 [19141248.001]

[Cites] Surgery. 1993 Dec;114(6):1050-7; discussion 1057-8 [8256208.001]

[Cites] Thyroid. 2007 Jul;17(7):639-46 [17696834.001]

[Cites] Asian J Surg. 2007 Apr;30(2):102-7 [17475578.001]

[Cites] J Clin Endocrinol Metab. 1990 Aug;71(2):414-24 [2380337.001]

[Cites] J Clin Oncol. 1997 May;15(5):2067-75 [9164219.001]

[Cites] Surgery. 1994 Dec;116(6):1036-40; discussion 1040-1 [7985084.001]

[Cites] Head Neck. 1998 Jan;20(1):26-30 [9464949.001]

[Cites] Surgery. 1988 Dec;104(6):947-53 [3194846.001]

[Cites] World J Surg. 2007 May;31(5):879-87 [17308849.001]

[Cites] Cancer Sci. 2008 Oct;99(10):1908-15 [19016749.001]

[Cites] Endocr Regul. 2008 Mar;42(1):29-33 [18333702.001]

[Cites] Clin Nucl Med. 2007 Jun;32(6):440-4 [17515749.001]

[Cites] Endocr Relat Cancer. 2007 Dec;14(4):1099-105 [18045961.001]

[Cites] J Clin Endocrinol Metab. 2003 Apr;88(4):1433-41 [12679418.001]

[Cites] World J Surg. 2007 Jul;31(7):1417-24 [17534542.001]

[Cites] Rev Med Chir Soc Med Nat Iasi. 2007 Oct-Dec;111(4):940-5 [18389784.001]

[Cites] Otolaryngol Head Neck Surg. 2008 Feb;138(2):200-3 [18241716.001]

[Cites] Endocrinol Metab Clin North Am. 1990 Sep;19(3):545-76 [2261906.001]

[Cites] J Clin Endocrinol Metab. 2009 Jun;94(6):2199-203 [19293266.001]

[Cites] Ann Surg Oncol. 1996 Nov;3(6):534-8 [8915484.001]

[Cites] Cancer. 1985 Feb 15;55(4):805-28 [3967175.001]

(PMID = 19485942.001).

[ISSN] 1512-8601

[Journal-full-title] Bosnian journal of basic medical sciences

[ISO-abbreviation] Bosn J Basic Med Sci

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Bosnia and Herzegovina

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Follicular carcinoma arising from the pyramidal lobe of the thyroid.

We present a rare case of follicular carcinoma arising from the pyramidal lobe of the thyroid in a 21-year-old woman.

Radical resection of the thyroid isthmus was performed, followed by adjuvant hormonal therapy with levothyroxine.

After 15 months of follow-up, the patient remains disease-free.

Thyroid carcinoma in children and adolescents is rare, and also rarely arises in the pyramidal lobe.

To our knowledge, this is the first report of this type of neoplasm arising from the thyroid pyramidal lobe.

This case suggests the importance of the differential diagnosis of midline cervical masses and the management of this type of neoplasm in adolescents.

[MeSH-major] Adenocarcinoma, Follicular / pathology. Thyroid Neoplasms / pathology

MedlinePlus Health Information. consumer health - Thyroid Cancer.

Hazardous Substances Data Bank. LEVOTHYROXINE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19602825.001).

[ISSN] 1345-4676

[Journal-full-title] Journal of Nippon Medical School = Nippon Ika Daigaku zasshi

[ISO-abbreviation] J Nippon Med Sch

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Japan

[Chemical-registry-number] Q51BO43MG4 / Thyroxine

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Utility of immunohistochemical markers in differentiating benign from malignant follicular-derived thyroid nodules.

BACKGROUND: Thyroid nodules are common among adults though only a small percentage is malignant, which can histologically mimic benign nodules.

Accurate diagnosis of these thyroid nodules is critical for the proper clinical management.

METHODS: We investigated immunoexpression in 98 surgically removed benign thyroid nodules including 52 hyperplastic nodules (HN) and 46 follicular/Hurthle cell adenomas (FA), and 54 malignant tumors including 22 follicular carcinoma (FC), 20 classic papillary carcinoma (PTC), and 12 follicular variant papillary carcinoma (FVPC).

RESULTS: The staining results showed that malignant tumors express galectin-3, HBME-1, CK19 and Ret oncoprotein significantly more than benign nodules.

The sensitivity of these markers for the distinction between benign and malignant lesions ranged from 83.3% to 87%.

Immunoexpression was usually diffuse and strong in malignant tumors, and focal and weak in the benign lesions.

CONCLUSION: Our findings indicate that these immunomarkers are significantly more expressed in malignant tumors compared to benign lesions and may be of additional diagnostic value when combined with routine histology.

[MeSH-major] Biomarkers, Tumor / analysis. Immunohistochemistry. Thyroid Nodule / diagnosis

[MeSH-minor] Adenocarcinoma, Follicular. Carcinoma. Diagnosis, Differential. Galectin 3 / analysis. Humans. Hyperplasia. Keratin-19 / analysis. Predictive Value of Tests. Proto-Oncogene Proteins c-ret / analysis. Sensitivity and Specificity. Thyroid Neoplasms / chemistry. Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / pathology

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Endocr Pathol. 2003 Spring;14(1):55-60 [12746563.001]

[Cites] Endocr Pathol. 2002 Fall;13(3):207-11 [12446919.001]

[Cites] Mod Pathol. 2003 Nov;16(11):1117-23 [14614051.001]

[Cites] Acta Chir Iugosl. 2003;50(3):67-70 [15179758.001]

[Cites] J Endocrinol Invest. 2004 Apr;27(4):311-7 [15233548.001]

[Cites] Ann Surg. 2004 Sep;240(3):425-36; discussion 436-7 [15319714.001]

[Cites] Am J Clin Pathol. 2004 Oct;122(4):524-31 [15487449.001]

[Cites] Anticancer Res. 1998 Jul-Aug;18(4A):2637-41 [9703921.001]

[Cites] Head Neck. 2004 Nov;26(11):960-6 [15386597.001]

[Cites] Mod Pathol. 2005 Jan;18(1):48-57 [15272279.001]

[Cites] Mod Pathol. 2005 Apr;18(4):541-6 [15529186.001]

[Cites] Histopathology. 2005 Oct;47(4):391-401 [16178894.001]

[Cites] Br J Cancer. 2005 Nov 14;93(10):1175-81 [16251880.001]

[Cites] Zhonghua Zhong Liu Za Zhi. 2005 Sep;27(9):547-50 [16438854.001]

[Cites] Acta Cytol. 2006 Jan-Feb;50(1):28-34 [16514837.001]

[Cites] Histopathology. 2006 Jun;48(7):795-800 [16722927.001]

[Cites] Indian J Pathol Microbiol. 2006 Jul;49(3):376-80 [17001889.001]

[Cites] Am J Clin Pathol. 2006 Nov;126(5):700-8 [17050067.001]

[Cites] Mod Pathol. 2006 Dec;19(12):1631-7 [16998461.001]

[Cites] Ann Pathol. 2006 Oct;26(5):347-51 [17255922.001]

[Cites] Endocr Pathol. 2006 Fall;17(3):213-23 [17308358.001]

[Cites] Endocr Pathol. 2006 Fall;17(3):225-34 [17308359.001]

[Cites] J Korean Med Sci. 2007 Aug;22(4):621-8 [17728499.001]

[Cites] Lancet Oncol. 2008 Jun;9(6):543-9 [18495537.001]

[Cites] Am J Clin Pathol. 2008 Nov;130(5):683-6 [18854259.001]

[Cites] Am J Clin Pathol. 2008 Nov;130(5):736-44 [18854266.001]

[Cites] Lancet. 2000 Dec 9;356(9246):2010-1 [11130546.001]

[Cites] Mod Pathol. 2001 Apr;14(4):338-42 [11301350.001]

[Cites] Lancet. 2001 May 26;357(9269):1644-50 [11425367.001]

[Cites] Am J Clin Pathol. 2001 Nov;116(5):696-702 [11710686.001]

[Cites] Arch Pathol Lab Med. 2002 Jun;126(6):710-3 [12033961.001]

[Cites] Diagn Cytopathol. 2002 Jun;26(6):366-72 [12112826.001]

[Cites] Histopathology. 2002 Sep;41(3):236-43 [12207785.001]

[Cites] Eur J Endocrinol. 2003 Nov;149(5):449-53 [14585093.001]

(PMID = 20181018.001).

[ISSN] 1746-1596

[Journal-full-title] Diagnostic pathology

[ISO-abbreviation] Diagn Pathol

[Language] eng

[Publication-type] Comparative Study; Evaluation Studies; Journal Article

[Publication-country] England

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Galectin 3; 0 / HBME-1 antigen; 0 / Keratin-19; EC 2.7.10.1 / Proto-Oncogene Proteins c-ret; EC 2.7.10.1 / RET protein, human; Thyroid cancer, Hurthle cell; Thyroid cancer, papillary

[Other-IDs] NLM/ PMC2831001

[General-notes] NLM/ Original DateCompleted: 20100524

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Muc-1 expression may help characterize thyroid nodules but does not predict patients' outcome.

Our purpose was to evaluate MUC1 clinical utility in the diagnosis and prognosis of thyroid cancer patients.

We studied the protein expression of MUC1 in 289 thyroid carcinomas and 121 noncancerous thyroid nodules.

There were 41 follicular carcinomas (FC) and 248 papillary thyroid carcinomas (PTC) including 149 classic (CPTC), 20 tall cell (TCPTC) and 79 follicular variants (FVPTC).

In addition, we used a quantitative real-time PCR (q-PCR) method to measure MUC1 mRNA expression levels in 108 carcinomas, 23 hyperplasias, and 19 FA.

According to their serum Tg levels and other evidences of recurrence/metastasis, the patients were classified as free-of-disease (185 cases) or bad outcome (56 cases, 10 deaths).

MUC1 protein was identified in 80.2% PTC; 48.8% FC; 68.3% FVPTC; 70% TCPTC; 21.8% FA; 30% hyperplasias and 6% normal thyroid tissues.

MUC1 distinguished benign from malignant thyroid tissues (sensitivity = 89%; specificity = 53%).

MUC1 also differentiated FC from FA (p = 0.0083).

q-PCR mRNA expression of MUC1 also distinguished malignant from benign nodules (Mann-Whitney test, p < 0.0001).

We suggest that MUC1 expression may help differentiate follicular patterned thyroid lesions.

[MeSH-major] Adenocarcinoma, Follicular / diagnosis. Carcinoma, Papillary / diagnosis. Mucin-1 / biosynthesis. Thyroid Neoplasms / diagnosis. Thyroid Nodule / diagnosis

MedlinePlus Health Information. consumer health - Thyroid Cancer.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Gastroenterol. 2003;38(12):1162-6 [14714254.001]

[Cites] Thyroid. 1997 Oct;7(5):725-31 [9349575.001]

[Cites] Thyroid. 2010 May;20(5):465-73 [20384488.001]

[Cites] Surgery. 2010 Sep;148(3):532-7 [20236675.001]

[Cites] Gastroenterology. 1994 Feb;106(2):353-61 [7905449.001]

[Cites] Cancer Cytopathol. 2010 Feb 25;118(1):17-23 [20099311.001]

[Cites] Hum Pathol. 1997 Sep;28(9):1056-65 [9308730.001]

[Cites] Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15044-9 [11752453.001]

[Cites] Laryngoscope. 2007 May;117(5):911-6 [17473695.001]

[Cites] Int J Cancer. 1996 Mar 28;66(1):55-9 [8608966.001]

[Cites] Thyroid. 2009 Nov;19(11):1167-214 [19860577.001]

[Cites] Laryngoscope. 2008 Apr;118(4):692-6 [18094649.001]

[Cites] J Clin Endocrinol Metab. 2001 Apr;86(4):1447-63 [11297567.001]

[Cites] Thyroid. 2004 Feb;14(2):99-111 [15068624.001]

[Cites] World J Surg. 2010 Jan;34(1):28-35 [20020290.001]

[Cites] Int J Biol Markers. 2000 Oct-Dec;15(4):343-56 [11192832.001]

[Cites] Int J Cancer. 1999 Jun 21;84(3):251-7 [10371342.001]

[Cites] Endocr Pathol. 2007 Summer;18(2):68-75 [17916995.001]

[Cites] Mod Pathol. 2008 Jun;21(6):748-55 [18360353.001]

[Cites] Am J Pathol. 2004 Jul;165(1):25-34 [15215159.001]

[Cites] Biol Pharm Bull. 2008 Dec;31(12):2288-93 [19043215.001]

[Cites] Zhonghua Yi Xue Za Zhi. 2009 Feb 17;89(6):393-6 [19567117.001]

[Cites] Mol Cell Endocrinol. 2010 Jun 30;322(1-2):8-28 [20138116.001]

[Cites] Cancer Res. 2004 Jun 1;64(11):3780-9 [15172984.001]

[Cites] Cancer Res. 2004 Mar 1;64(5):1821-7 [14996745.001]

[Cites] Cancer. 2001 Jun 1;91(11):1973-82 [11391575.001]

[Cites] Mol Cell Endocrinol. 2010 May 28;321(1):86-93 [19883729.001]

(PMID = 21057891.001).

[ISSN] 1559-0097

[Journal-full-title] Endocrine pathology

[ISO-abbreviation] Endocr. Pathol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MUC1 protein, human; 0 / Mucin-1; 0 / RNA, Messenger

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Familial non-medullary thyroid carcinoma: an update.

Familial thyroid cancer can arise from follicular cells (familial non-medullary thyroid carcinoma (FNMTC)) or from the calcitonin-producing C-cell (familial medullary thyroid carcinoma).

This is usually a component of multiple endocrine neoplasias (MEN) IIA or IIB, or as pure familial medullary thyroid carcinoma syndrome.

The genetic events in the familial C-cell-derived tumors are known and genotype-phenotype correlations are well established.

In contrast, the case for a familial predisposition of non-medullary thyroid carcinoma is only now beginning to emerge.

Although the majority of papillary (PTC) and follicular thyroid carcinomas (FTC) are sporadic, familial tumors account for over 5% of cases.

The presence of multifocal papillary carcinoma is a common feature of FNMTC.

The familial follicular cell-derived tumors or non-medullary thyroid carcinomas encompass a heterogeneous group of diseases, including diverse syndromic-associated tumors and non-syndromic tumors.

The first includes familial syndromes characterized by a predominance of non-thyroidal tumors, such as familial adenomatous polyposis (FAP), PTEN hamartoma tumor syndrome (PHTS), Carney complex type 1, and Werner syndrome.

The second group includes familial syndromes characterized by a predominance of NMTC, such as pure familial (f) PTC with or without oxyphilia, fPTC with papillary renal cell carcinoma, and fPTC with multinodular goiter.

Some characteristic morphologic findings should alert the pathologist of a possible familial cancer syndrome, which may lead to further molecular genetic evaluation.

[MeSH-major] Carcinoma, Papillary, Follicular / genetics. Hamartoma Syndrome, Multiple / genetics. Multiple Endocrine Neoplasia / genetics. Thyroid Neoplasms / genetics

[MeSH-minor] Adult. Child, Preschool. Humans. Infant. Middle Aged. Thyroid Gland / pathology

MedlinePlus Health Information. consumer health - Thyroid Cancer.

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Endocr Pathol. 2001 Summer;12(2):97-112 [11579685.001]

[Cites] World J Surg. 2006 May;30(5):787-93 [16479341.001]

[Cites] J Pathol. 1998 Nov;186(3):292-9 [10211119.001]

[Cites] N Engl J Med. 1996 Sep 26;335(13):943-51 [8782503.001]

[Cites] Ann N Y Acad Sci. 2000 Jun;908:167-79 [10911957.001]

[Cites] Expert Rev Mol Diagn. 2008 Jan;8(1):83-95 [18088233.001]

[Cites] J Clin Endocrinol Metab. 1996 Apr;81(4):1619-22 [8636377.001]

[Cites] Hum Mol Genet. 1999 Aug;8(8):1461-72 [10400993.001]

[Cites] World J Surg. 2006 May;30(5):775-9 [16680592.001]

[Cites] Am J Surg Pathol. 2002 Aug;26(8):1016-23 [12170088.001]

[Cites] Am J Pathol. 1999 Jan;154(1):127-35 [9916927.001]

[Cites] J Clin Endocrinol Metab. 1998 Aug;83(8):2972-6 [9709978.001]

[Cites] Oncology. 1975;32(3-4):151-7 [1241121.001]

[Cites] Am J Clin Pathol. 2003 Jul;120(1):71-7 [12866375.001]

[Cites] Endocr Pathol. 2002 Spring;13(1):3-16 [12114746.001]

[Cites] Expert Rev Mol Diagn. 2005 Jul;5(4):573-84 [16013975.001]

[Cites] Thyroid. 2005 Jun;15(6):588-93 [16029126.001]

[Cites] J Pathol. 1999 Nov;189(3):387-93 [10547601.001]

[Cites] JAMA. 2006 May 10;295(18):2164-7 [16684987.001]

[Cites] J Clin Endocrinol Metab. 1997 Feb;82(2):345-8 [9024215.001]

[Cites] N Engl J Med. 2005 Sep 15;353(11):1105-13 [16162881.001]

[Cites] Ann Diagn Pathol. 1999 Dec;3(6):331-40 [10594284.001]

[Cites] J Clin Endocrinol Metab. 2000 May;85(5):1758-64 [10843148.001]

[Cites] Histopathology. 1994 Dec;25(6):549-61 [7698732.001]

[Cites] Endocrinology. 2007 Mar;148(3):936-41 [16946010.001]

[Cites] Endocr Pathol. 2005 Fall;16(3):163-72 [16299399.001]

[Cites] Oncology. 1991;48(4):309-11 [1891173.001]

[Cites] World J Surg. 2002 Aug;26(8):897-902 [11965446.001]

[Cites] J Endocrinol Invest. 1998 Jun;21(6):358-64 [9699127.001]

[Cites] Curr Opin Oncol. 2001 Jan;13(1):44-51 [11148685.001]

[Cites] Thyroid. 2004 Nov;14(11):946-52 [15671773.001]

[Cites] Am J Surg Pathol. 2005 Feb;29(2):254-74 [15644784.001]

[Cites] J Clin Endocrinol Metab. 2003 May;88(5):2318-26 [12727991.001]

[Cites] Cancer. 1998 Dec 15;83(12):2638-48 [9874472.001]

[Cites] Mod Pathol. 1999 Apr;12(4):400-11 [10229505.001]

[Cites] N Engl J Med. 2006 Nov 30;355(22):2349-57 [17135589.001]

[Cites] J Clin Endocrinol Metab. 2005 Oct;90(10):5747-53 [16030170.001]

[Cites] Adv Anat Pathol. 1998 May;5(3):196-201 [9868525.001]

[Cites] AMA Arch Surg. 1955 Jun;70(6):923-8 [14375516.001]

[Cites] Am J Surg Pathol. 2003 Feb;27(2):266-7 [12548176.001]

[Cites] Clin Gastroenterol Hepatol. 2007 Mar;5(3):367-73 [17258512.001]

[Cites] Thyroid. 2006 Feb;16(2):181-6 [16613533.001]

[Cites] J Pathol. 2003 Jan;199(1):58-67 [12474227.001]

[Cites] Lancet. 1999 Feb 20;353(9153):637-9 [10030330.001]

[Cites] Cancer. 1999 Mar 15;85(6):1345-52 [10189141.001]

[Cites] Cancer Res. 1996 May 1;56(9):2167-70 [8616867.001]

[Cites] Cancer Control. 2006 Apr;13(2):106-10 [16735984.001]

[Cites] Arch Surg. 1996 Jun;131(6):676 [8645080.001]

[Cites] JAMA. 1996 Nov 20;276(19):1575-9 [8918855.001]

[Cites] Arch Surg. 1995 Aug;130(8):892-7; discussion 898-9 [7632152.001]

[Cites] Cancer. 2000 Mar 1;88(5):1139-48 [10699905.001]

[Cites] Thyroid. 2003 Jul;13(7):621-9 [12964966.001]

[Cites] Cancer Epidemiol Biomarkers Prev. 1996 Apr;5(4):239-46 [8722214.001]

[Cites] Clin Endocrinol (Oxf). 1999 May;50(5):589-94 [10468924.001]

[Cites] J Med Genet. 2007 Sep;44(9):579-85 [17526800.001]

[Cites] Endocr Pathol. 2004 Spring;15(1):55-64 [15067177.001]

[Cites] Nat Rev Cancer. 2007 Jan;7(1):35-45 [17167516.001]

[Cites] Cancer. 1995 Aug 1;76(3):479-89 [8625130.001]

[Cites] Thyroid. 2004 Dec;14(12):1056-60 [15650358.001]

[Cites] World J Surg. 2000 Nov;24(11):1409-17 [11038215.001]

[Cites] Cancer Res. 2003 Apr 1;63(7):1454-7 [12670889.001]

[Cites] Endocr Relat Cancer. 2006 Jun;13(2):475-83 [16728575.001]

[Cites] Hum Pathol. 2007 Dec;38(12):1810-8 [17714762.001]

[Cites] Surgery. 2000 Dec;128(6):1043-50;discussion 1050-1 [11114641.001]

[Cites] Clin Endocrinol Metab. 1981 Jul;10(2):351-65 [7285384.001]

[Cites] Tumori. 2007 Jan-Feb;93(1):109-11 [17455883.001]

[Cites] Thyroid. 1999 Mar;9(3):247-52 [10211600.001]

[Cites] Cancer. 1996 Feb 15;77(4):750-6 [8616768.001]

[Cites] J Clin Endocrinol Metab. 1999 Jun;84(6):2157-62 [10372725.001]

[Cites] J Clin Endocrinol Metab. 2003 Nov;88(11):5399-404 [14602780.001]

[Cites] Nat Rev Cancer. 2006 Apr;6(4):292-306 [16557281.001]

[Cites] J Clin Endocrinol Metab. 2001 Aug;86(8):3701-4 [11502798.001]

[Cites] J Med Genet. 2001 Jan;38(1):52-8 [11332402.001]

[Cites] J Clin Endocrinol Metab. 2008 Mar;93(3):682-7 [18073307.001]

[Cites] Hum Mutat. 2003 Sep;22(3):183-98 [12938083.001]

[Cites] Cancer. 1984 Apr 15;53(8):1790-2 [6697317.001]

[Cites] Am J Hum Genet. 2001 Aug;69(2):440-6 [11438887.001]

[Cites] Recent Prog Horm Res. 1999;54:441-52; discussion 453 [10548886.001]

[Cites] J Surg Oncol. 2006 Dec 15;94(8):662-9 [17131411.001]

[Cites] J Clin Endocrinol Metab. 1997 Jan;82(1):39-41 [8989229.001]

[Cites] Hum Mol Genet. 1998 Mar;7(3):507-15 [9467011.001]

[Cites] Nature. 1994 Jan 27;367(6461):375-6 [7906866.001]

[Cites] Adv Anat Pathol. 2006 Mar;13(2):69-75 [16670460.001]

[Cites] Am J Surg Pathol. 2007 Sep;31(9):1337-43 [17721188.001]

[Cites] N Engl J Med. 2003 Oct 16;349(16):1517-25 [14561794.001]

[Cites] Am J Hum Genet. 1997 Nov;61(5):1123-30 [9345104.001]

[Cites] Eur J Endocrinol. 1999 Aug;141(2):122-5 [10427154.001]

[Cites] J Clin Endocrinol Metab. 1997 Jul;82(7):2037-43 [9215269.001]

[Cites] J Clin Endocrinol Metab. 2000 Jan;85(1):286-92 [10634400.001]

[Cites] Cancer. 1985 Aug 1;56(3):531-8 [2408737.001]

[Cites] Clin Endocrinol (Oxf). 2005 Sep;63(3):263-6 [16117812.001]

[Cites] Mol Cell Endocrinol. 2008 Mar 12;284(1-2):21-7 [18282654.001]

[Cites] Am J Hum Genet. 1998 Dec;63(6):1743-8 [9837827.001]

(PMID = 18931957.001).

[ISSN] 1046-3976

[Journal-full-title] Endocrine pathology

[ISO-abbreviation] Endocr. Pathol.

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

[Number-of-references] 97

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Clinically significant prognostic factors for differentiated thyroid carcinoma: a population-based, nested case-control study.

BACKGROUND: Different scoring systems currently are being used to stratify patients with differentiated thyroid carcinoma (DTC) into risk groups.

DTC is usually subdivided into papillary thyroid carcinoma (PTC) and follicular thyroid carcinoma (FTC).

METHODS: The authors conducted a nested case-control study within the cohort of all patients (n=5123) diagnosed with DTC in Sweden between 1958-1987 who survived at least 1 year after diagnosis.

One control, matched by age at diagnosis, gender, and calendar period, was randomly selected for each case (patients who died of DTC).

All patients were classified at the time of diagnosis according to the TNM staging system.

RESULTS: Patients with widely invasive FTC experienced a significantly higher mortality compared with PTC patients.

Patients with TNM Stage IV disease had a higher mortality rate compared with patients with Stage II disease (odds ratio [OR]=9.1; 95% confidence interval [95% CI], 5.7-14.6).

Patients with lymph node metastases experienced a higher mortality (OR=2.5; 95% CI, 1.6-4.1) and patients with distant metastasis at the time of diagnosis were found to have a nearly 7-fold higher mortality rate (OR=6.6; 95% CI, 4.1-10.5).

Incomplete surgical excision was associated with higher mortality, particularly in patients with Stage I disease.

[MeSH-major] Adenocarcinoma, Follicular / pathology. Carcinoma, Papillary / pathology. Neoplasm Staging / standards. Thyroid Neoplasms / pathology

[MeSH-minor] Adult. Aged. Aged, 80 and over. Case-Control Studies. Diagnosis, Differential. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Prognosis. Registries / statistics & numerical data. Risk Assessment

MedlinePlus Health Information. consumer health - Thyroid Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright (c) 2005 American Cancer Society.

(PMID = 16369995.001).

[ISSN] 0008-543X

[Journal-full-title] Cancer

[ISO-abbreviation] Cancer

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] New therapeutic advances in the management of progressive thyroid cancer.

The spectrum of thyroid cancers ranges from one of the most indolent to one of the most aggressive solid tumors identified.

Conventional therapies for thyroid cancers are based on the histologic type of thyroid cancers such as papillary or follicular thyroid cancer (differentiated thyroid cancer (DTC)), medullary thyroid cancer (MTC), or anaplastic thyroid cancer (ATC).

While surgery is one of the key treatments for all such types of thyroid cancers, additional therapies vary.

Effective targeted therapy for DTC is a decades-old practice with systemic therapies of thyroid stimulating hormone suppression and radioactive iodine therapy.

Recent advances in understanding pathogenesis of DTC and development of molecular targeted therapy have dramatically transformed the field of clinical research in thyroid cancer.

Over the last five years, incredible progress has been made and phases I-III clinical trials have been conducted in various types of thyroid cancers with some remarkable results that has made an impact on lives of patients with thyroid cancer.

Such history-making events have boosted enthusiasm and interest among researchers, clinicians, patients, and sponsors and we anticipate ongoing efforts to develop more effective and safe therapies for thyroid cancer.

[MeSH-major] Antineoplastic Protocols. Carcinoma / therapy. Thyroid Neoplasms / therapy

[MeSH-minor] Animals. Carcinoma, Medullary / etiology. Carcinoma, Medullary / therapy. Carcinoma, Papillary / etiology. Carcinoma, Papillary / therapy. Clinical Trials as Topic / methods. Clinical Trials as Topic / trends. Disease Progression. Drug Evaluation, Preclinical / methods. Drug Evaluation, Preclinical / trends. Humans. Models, Biological

Genetic Alliance. consumer health - Thyroid Cancer.

MedlinePlus Health Information. consumer health - Thyroid Cancer.

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19218279.001).

[ISSN] 1479-6821

[Journal-full-title] Endocrine-related cancer

[ISO-abbreviation] Endocr. Relat. Cancer

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] England

[Number-of-references] 106

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Treatment and follow up protocol in differentiated thyroid carcinomas of follicular origin].

[Transliterated title] Protocolo de tratamento e seguimento dos carcinomas diferenciados da tiróide de origem folicular.

Differentiated thyroid carcinoma of follicular origin (DTCFO), although not very frequent, has registered a raising incidence in the last decades.

In the majority of the cases, DTCFO is a curable disease when treated and monitored by experienced, multidisciplinary teams.

The present protocol represents the consensus of the members of the Grupo de Estudo da Tiróide of the Sociedade Portuguesa de Endocrinologia, Diabetes e Metabolismo.

[MeSH-major] Thyroid Neoplasms / therapy

MedlinePlus Health Information. consumer health - Thyroid Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16202330.001).

[ISSN] 1646-0758

[Journal-full-title] Acta médica portuguesa

[ISO-abbreviation] Acta Med Port

[Language] por

[Publication-type] English Abstract; Journal Article; Practice Guideline; Research Support, Non-U.S. Gov't; Review

[Publication-country] Portugal

[Number-of-references] 120

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Myopathy following postoperative ablative radioiodine for follicular carcinoma of the thyroid.

We highlight a case of disabling myopathy following radioablative iodine treatment for follicular carcinoma of the thyroid.

A 34-year-old man presented with a tender neck swelling, ultrasound and biopsy were suggestive of thyroid malignancy.

Thyroidectomy was undertaken and histology confirmed follicular carcinoma of the thyroid.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 23754875.001).

[ISSN] 1179-142X

[Journal-full-title] International medical case reports journal

[ISO-abbreviation] Int Med Case Rep J

[Language] eng

[Publication-type] Journal Article

[Publication-country] New Zealand

[Other-IDs] NLM/ PMC3658207

[Keywords] NOTNLM ; iodine radioisotopes / muscular diseases / thyroid neoplasms

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Usefulness of galectin-3 expression in the clinical behavior of differentiated thyroid carcinoma].

[Transliterated title] Utilidad de la expresión de galectina-3 en el comportamiento clínico del cáncer diferenciado de tiroides.

BACKGROUND AND OBJECTIVE: Our objective was to quantify the galectin-3 (gal-3) expression in differentiated thyroid carcinoma and study its relation with the clinical behavior of these tumors.

PATIENTS AND METHOD: We investigated the immunohistochemical reaction of gal-3 in patients with papillary thyroid carcinoma (PTC) and follicular thyroid carcinoma (FTC) and performed a retrospective study in order to find correlations with clinical features.

Gal-3 expression was studied in 53 differentiated tyroid carcinomas (42 PTC and 11 FTC), and was related with clinical features: metastases, extrathyroid invasion and initial stage in the diagnosis and persistence disease and relapses in the follow up.

RESULTS: Gal-3 expression positivity in PTC had a median of 60% (percentil 25 [p25], 17.5%; percentil 75 [p75], 100%), and was significantly higher (p < 0.0001) than in FTC (median, 0%; p25, 0%; p75, 15%).

In PTC, gal-3 expression was significantly higher in advanced stages at the time of initial diagnosis (p = 0.014), persistent disease (p = 0.012) and relapses (p = 0.012) during the follow up.

We did not find any significant association between gal-3 expression and clinical features of FTC.

CONCLUSIONS: Gal-3 is a negative prognosis marker in PTC but not in FTC.

[MeSH-major] Carcinoma, Papillary / metabolism. Galectin 3 / biosynthesis. Thyroid Neoplasms / metabolism

MedlinePlus Health Information. consumer health - Thyroid Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18341829.001).

[ISSN] 0025-7753

[Journal-full-title] Medicina clínica

[ISO-abbreviation] Med Clin (Barc)

[Language] spa

[Publication-type] English Abstract; Journal Article

[Publication-country] Spain

[Chemical-registry-number] 0 / Galectin 3

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Pattern of regional metastases and prognostic factors in differentiated thyroid carcinoma.

The meaning of nodal metastases in well-differentiated thyroid carcinoma is controversial.

The Authors analyse the impact of lymphatic spread reviewing 1503 cases of well-differentiated thyroid carcinoma treated at the National Cancer Institute of Rome between 1988 and 2005, in order to detect significant prognostic factors through multivariate analysis.

Overall, 462 cases of locally advanced well-differentiated thyroid carcinoma, were considered.

A multivariate analysis of a subgroup, comprising 97 N+ consecutive cases of well-differentiated thyroid carcinoma, previously untreated, was performed to study prognostic factors for local (N+) and distant (M+) metastasis in well-differentiated thyroid carcinoma.

Of the 97 cases, 88 were submitted to surgery for a large well-differentiated thyroid carcinoma, 9 for occult differentiated thyroid carcinoma.

After surgery, 12 patients were lost to follow-up, 8 resulted pathologically negative, therefore only 77 cases of pN1 well-differentiated thyroid carcinoma were studied.

Considering all cases of well-differentiated thyroid carcinoma, 10-year-overall survival was 58.7% for locally advanced well-differentiated thyroid carcinoma, compared to 94.8% in low stage cases.

The Authors present a retrospective study of 77 patients with primary differentiated thyroid carcinoma, submitted to thyroidectomy and neck dissection aimed at analysing distribution of nodal metastases according to Robbins' levels classification and defining their prognostic value.

All N1b cases, retrospectively reviewed (n. 77), presented clinical and histological evidence of neck nodes metastases from differentiated thyroid carcinoma; histological reports indicated tumour localisation and topographical distribution of metastases; papillary carcinoma was the most common type (72 cases), followed by follicular carcinoma (5 cases).

Statistically significant prognostic factors for distant metastases and recurrence on the neck were follicular carcinoma (p < 0.01) and extra-capsular spread (p < 0.001).

In the Authors' experience, histological grade of differentiation, wide tumour excision and neck dissection, in cases of N1b well-differentiated thyroid carcinoma, without residual disease (R1, R2), in the central and lateral neck, are determinant prognostic factors.

[MeSH-major] Carcinoma, Papillary / secondary. Thyroid Neoplasms / pathology

[MeSH-minor] Adenocarcinoma, Follicular. Adolescent. Adult. Aged. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Prognosis. Retrospective Studies. Young Adult

MedlinePlus Health Information. consumer health - Thyroid Cancer.

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Laryngoscope. 1992 May;102(5):486-91 [1573942.001]

[Cites] Surgery. 2006 Dec;140(6):1050-4; discussion 1054-5 [17188156.001]

[Cites] J Exp Clin Cancer Res. 1997 Sep;16(3):333-5 [9387910.001]

[Cites] Br J Surg. 1998 Feb;85(2):252-4 [9501829.001]

[Cites] Otolaryngol Clin North Am. 1998 Oct;31(5):823-31 [9735110.001]

[Cites] World J Surg. 1999 Sep;23(9):970-3; discussion 973-4 [10449830.001]

[Cites] Cancer. 1975 Sep;36(3):1138-46 [1182668.001]

[Cites] Ann Surg. 1976 Nov;184(5):541-53 [984923.001]

[Cites] Am J Surg. 1978 Jul;136(1):107-12 [567016.001]

[Cites] Cancer. 1979 Mar;43(3):810-20 [427722.001]

[Cites] Arch Otolaryngol Head Neck Surg. 2006 Jun;132(6):650-4 [16785411.001]

[Cites] Vestn Khir Im I I Grek. 2005;164(6):48-51 [16792315.001]

[Cites] Am J Med. 1981 Mar;70(3):511-8 [7211893.001]

[Cites] Cancer. 1985 Feb 15;55(4):794-804 [3967174.001]

[Cites] Surgery. 1985 Dec;98(6):1171-8 [4071392.001]

[Cites] Cancer. 1986 Apr 1;57(7):1405-14 [3948123.001]

[Cites] Mayo Clin Proc. 1986 Dec;61(12):978-96 [3773569.001]

[Cites] Surg Clin North Am. 1987 Apr;67(2):251-61 [3551147.001]

[Cites] Am J Surg. 1990 Oct;160(4):344-7 [2221232.001]

[Cites] Arch Otolaryngol Head Neck Surg. 1991 Jun;117(6):601-5 [2036180.001]

[Cites] Folia Med (Plovdiv). 2006;48(1):17-22 [16918050.001]

[Cites] Laryngoscope. 2006 Nov;116(11):2081-5 [17075398.001]

[Cites] J Surg Oncol. 2006 Dec 15;94(8):683-91 [17131422.001]

[Cites] Ann Ital Chir. 2006 Mar-Apr;77(2):107-13 [17147082.001]

[Cites] Head Neck. 1996 Mar-Apr;18(2):127-32 [8647677.001]

(PMID = 20463835.001).

[ISSN] 1827-675X

[Journal-full-title] Acta otorhinolaryngologica Italica : organo ufficiale della Società italiana di otorinolaringologia e chirurgia cervico-facciale

[ISO-abbreviation] Acta Otorhinolaryngol Ital

[Language] eng

[Publication-type] Journal Article

[Publication-country] Italy

[Other-IDs] NLM/ PMC2868202

[Keywords] NOTNLM ; Extra-capsular spread / Nodal metastases / Thyroid carcinoma